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The morbidity and mortality of cancer typically arises from metastasis of the primary 
tumor and it is generally accepted that secondary prevention through early detection 
yields the opportunity for early intervention. Spreading of cancer to distant sites is 
usually established through the body circulatory system and thus the number of 
circulating tumor cells (CTCs) in peripheral blood of cancer patients is strongly 
associated to the disease development. The technical challenge lies in the rarity of these 
cells in peripheral blood of cancer patients which makes them hard to be distinguished. 
Recent advances in microdevice technology have allowed highly sensitive techniques, 
and the current investigation seeks to demonstrate a system for the effective isolation and 
study of CTCs. The study presents a label-free microdevice that is capable of isolating 
cancer cells from whole blood via cancer cells’ distinctively different physical properties 
such as size and deformability. The isolation of CTCs using microfluidics is attractive as 
the flow conditions can be accurately manipulated to achieve an efficient separation. 
Using physical structures placed in the path of blood specimens in a microchannel, CTCs 
which are generally larger and stiffer are retained while most blood constituents are 
removed. The operations for processing blood are straightforward and permit 
multiplexing of the microdevices to concurrently work with different samples. The 
microfluidic device is optically transparent which makes it simple to be integrated to 
existing laboratory microscopes and immunofluorescence staining can be done in situ to 
distinguish cancer cells from hematopoietic cells. This also minimizes the use of 




In the development of this microfluidic device, computational studies of the proposed 
microfluidic design along with results from feasibility studies are first performed. A full 
characterization of the microdevice with numerous cancer cell lines from different origins 
is then conducted. Finally, its direct use with clinical blood specimens is investigated. 
With the microfluidic system, it was demonstrated that an effective isolation could be 
attained and the microdevice is versatile to address the heterogeneities associated with 
different cancer types. The microsystem was verified with studies using cancer cell lines 
from breast, colorectal, gastric, liver, tongue and throat cancer. Using clinical blood 
specimens, isolation of CTCs was achieved with high sensitivity and attained close to 100% 
detection rate. Due to the unique separation technique, it also enabled the capture of a 
more diverse group of CTCs without the use of antibodies during enrichment. With this 
system, real-time visualization of CTC isolation can be achieved during blood processing. 
The microdevice shows promise in the isolation and investigation of CTCs on patients 
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Chapter 1 Introduction 
 
1.1 Background (Disease and Technology) 
 
Cancer has been the interest of medical research for over a century and is usually 
associated with extreme desperation in patients due to the morbidity and fatalities 
involved. In 2008 alone, 7.6 million people die from the disease, with an estimation of 
over 12.6 million newly diagnosed cases (Ferlay J 2008) according to the World Health 
Organization (WHO). The lack of telltale signs at the onset limits the ability for 
eradicating or early treatment of cancer (Chambers, Groom et al. 2002). Physical signs 
associated with the disease include the uncontrolled proliferation of cells which can affect 
almost any part of the body. More often than not, these signs go unnoticed until serious 
impairment of bodily functions or pain is experienced. In most cases, the primary cause 
of cancer related deaths is the result of the intravasation of tumor cells from the primary 
neoplasm into the circulation and the subsequent growth of a secondary tumor at distant 
sites (Heyder, Gloria-Maercker et al. 2006; Steeg 2006), a process known as metastasis. 
The exact mechanism of how tumors spread remains an enigma, although there were 
early observations showing possibilities of targeted cancer spreading to specific organs in 
the human body (Paget 1889). In more recent investigations, the pathogenesis of cancer 
metastasis is now better understood after decades of extensive studies (Gupta and 





As shown in figure 1.1a, the disease establishes with a local aberration of cellular 
functions at the genetic level, leading to malignant transformation and tumor growth. 
Subsequently, cell proliferation results in increase tumor mass and extensive 
vascularization supplies continual nutrients to maintain growth. The invasion or 
intravasation of tumor cells into the host stroma provides entry into the circulation where 
cancer cells become free to colonize a secondary site as shown in figure 1.1f. This cycle 
Figure 1.1 Major steps in the metastatic progression of cancer. (a) Cellular aberration and 
tumor growth. (b) Formation of blood vessels to sustain and replenish nutrients to the tumor. 
(c-d) Intravastion of tumor cells into the stroma tissue and dissemination through the 
circulation. (e-f) Tumor arrest and extravastion to form secondary metastases. (Fidler 2003) 
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occurs repeatedly which translates into an aggravation of the disease for the patient. 
Important events in the biological cascade of cancer metastasis are the uncontrolled cell 
proliferation, angiogenesis and tumor dissemination into the circulation. These processes 
sustain the growth and allow the progression of the disease. An estimated 90% of deaths 
from solid tumors are a direct result of metastasis (Gupta and Massague 2006). Therefore 
effective means to combat the disease are through early detection before metastasis has 
occurred or to prevent the spread of the tumor cells to distant sites of the body.  
 
Technological advances have brought significant improvements in diagnostic methods, 
surgical techniques, general patient care and enhanced therapeutic treatments (Spinney 
2006). For instance, the use of nano-particles achieved the targeted delivery of anti-
cancer drugs directly to tumor cells, aiming to avoid debilitating outcomes with 
conventional chemotherapeutic treatments (MacDiarmid, Mugridge et al. 2007). The 
development of better imaging techniques such as the positron-emission tomography 
(PET) scan have proved useful in patients with non-small cell lung cancer (NSCLC) as 
compared to standard approaches using computed tomography (CT), ultrasonography and 
bone scanning (Pieterman, van Putten et al. 2000). As technology develops, it will 
increasingly have a broader impact in biology and healthcare, bringing more sensitive 
instruments for various clinical applications. This in turn hopes to improve the quality of 
life for patients. The need for better techniques in cancer detection cannot be 
overemphasized, given the increasing trend of people suffering or dying from the disease. 
New devices which are more sensitive and convenient in the clinical setting are necessary 
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to better detect tumors in the body so that they can be effectively eliminated before 
acquiring the ability to metastasize.  
 
 
1.1.1 Circulating Tumor Cells  
 
Cancer cells that enter the blood circulation are termed as circulating tumor cells (CTCs), 
with documented evidence of the presence of CTCs over a century ago (Ashworth 1869) 
during the examination of blood samples from a deceased patient. In more recent 
evaluations, CTCs are found in patients with different metastatic carcinomas (Allard, 
Matera et al. 2004; Steen, Nemunaitis et al. 2008) and clinical studies supported the 
potential use of the number of CTCs in peripheral blood as prognostic indicators for 
survival in metastatic breast, prostate and colon cancers (Cristofanilli, Hayes et al. 2005; 
Slade and Coombes 2007; de Bono, Scher et al. 2008; Helo, Cronin et al. 2009). Thus, 
analyzing the blood specimens of patients which are routinely taken can be useful and is 
also less invasive as compared with traditional biopsies. Evidence from various clinical 
investigations have also showed that CTC count in blood is directly linked to disease 
progression, overall survival (Cristofanilli, Budd et al. 2004; Nole, Munzone et al. 2008) 
and an indication of treatment efficacy (Reuben, Krishnamurthy et al. 2008; Serrano, 
Sanchez-Rovira et al. 2009). Comparing to invasive biopsies, the enumeration of CTCs in 
peripheral blood provides a promising alternative source of tumour tissue for the 
detection, characterisation and monitoring of non-blood-related cancers. Thus, isolating, 




Research into tumor cell dissemination through the circulatory system has shown it to be 
an inefficient process and most of the tumor cells are destroyed before distant 
implantation can occur (Weiss 1990; Brodland and Zitelli 1992; Weiss 1992). As a result, 
the frequency of CTCs in peripheral blood of cancer patients is of very low concentration 
and varying in quantity from patient to patient (Zieglschmid, Hollmann et al. 2005; 
Losanoff, Zhu et al. 2008). The rarity of CTCs in peripheral blood presents a technical 
challenge to detect them (Pantel, Cote et al. 1999). Tumor cell count can be as low as 1 
cancer cell to 1 ml of blood which contains approximately 4.8 – 5.4 billion erythrocytes; 
7.4 million leukocytes and 280 million thrombocytes (Fournier 1998). Several different 
enrichment methodologies have been employed to isolate CTCs, most notably using 
biochemical means. Using anti-bodies targeted against epithelial specific antigens such as 
Epithelial Cell Adhesion Molecule (EpCAM), CTCs have been isolated using magnetic 
separation or flow based assays (Nagrath, Sequist et al. 2007; Riethdorf, Fritsche et al. 
2007). Additional immunofluorescence staining or molecular based techniques are 
utilized to confirm the presence of CTCs in the isolated cell population, allowing them to 
be distinguished from hematopoietic cells. The procedure is demonstrated in various 
clinical settings but studies have established that the effectiveness is highly dependent on 
the specificity of the anti-body used (Sieuwerts, Kraan et al. 2009). Alternative 
methodologies such as a direct visualization assay (Kahn, Presta et al. 2004), fluorescent 
activated cell sorter (FACS) (Moreno, O'Hara et al. 2001) and fibre-optic array scanning 
technology (FAST) cytometer (Krivacic, Ladanyi et al. 2004) have also been used to 
detect CTCs in blood samples. Complex procedures, tedious inspections and long 
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processing time are the limiting factors associated with most existing techniques. 
Furthermore, viability of the isolated cells is lost during the process as fixations of the 
samples are required by most existing techniques. The understanding of the molecular 
and biological characteristics of CTCs and their connections to the metastatic process is 
in its infancy but these tumor cells hold important information about the disease (Pantel 
and Alix-Panabieres 2007). 
 
There is much to appreciate about the conditions of CTCs whilst in circulation (Pantel, 
Brakenhoff et al. 2008) and having viable cells after isolation will allow studies to be 
carried out on CTC sub-populations. This may provide valuable insights into the 
metastatic process which will influence therapeutic decisions. Thus a sensitive 
enrichment method is crucial to aid in further examination of CTCs which can be 
clinically beneficial. Taken together, the enumeration of CTCs in peripheral blood is a 
promising and attractive complementary technique for the detection, investigation and 





Biological cells, typically in the range of several microns to tens of microns, are 
extremely hard to handle for its small size. Precise control and instrumentation are 
required to work at such resolutions to correctly position the cell to the desired location 
for measurements to be taken (Van Vliet, Bao et al. 2003). Traditional bench-top tools in 
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cell and molecular biology are not sufficient to address the needs for sensitive and 
accurate measurements of rare cell events such as the isolation and enumeration of CTCs. 
The advent of various breakthroughs in micro and nano technology has aided the 
development of numerous manipulation and analytical methods for various qualitative 
and quantitative analyses. Techniques that are built upon engineering principles such as 
microelectronics as well as cell and nuclear mechanics have enabled the handling of 
micron and sub micron size objects or samples accurately. These methodologies also 
offer a high throughput analysis using small sample volumes (Bashir 2004; Whitesides 
2006) and make these technologies suitable to handle the challenges involved in single 
cell and nucleus manipulations, and analyze the molecular components such as DNA and 
RNA (Thorsen, Maerkl et al. 2002; Hong and Quake 2003).  
 
Microfluidics involves the miniaturization of systems for the handling and manipulation 
of small quantities of fluids. With microchannels in the dimensions of a few to hundreds 
of micrometers, it is well suited for single cell handling which is of comparable 
dimensions. The small size in microfluidic devices ensures laminar flow characteristics 
(low Reynolds number) which make the fluid flow predictable. The flow characteristics 
of such systems will further aid in the precise control of cells in the enclosed environment. 
A vast number of applications are being developed based on the technology which 
includes analytical systems in biochemistry, biomedical devices for disease detection and 
tools used in systems biology (Whitesides, Ostuni et al. 2001; Smith and Figeys 2006; 
Martini, Hellmich et al. 2007; Ohno, Tachikawa et al. 2008). Besides being suitable to 
handle single cells analyses, other motivations for using microfluidic platforms are 
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abundant.  It provides a quick means to test out designs due to the fast turnover time and 
offers the ability to integrate several devices with various functions to form a complete 
integrated laboratory on chip (Melin and Quake 2007). Furthermore, the miniaturized 
platform allows for minimal use of expensive reagents compared to similar conventional 
biological bench-top methods, thereby saving cost. The technology fundamentally 
introduces myriad possibilities to enhance and bring about new capabilities in a variety of 
analyses (Sorger 2008). Hence, microfluidic devices can be especially useful in 
investigating rare cell events like the detection of CTCs in peripheral blood.  
 
 
1.2 Motivations, Hypothesis and Objectives 
 
According to the American Cancer Society, about a third of patients (excluding non-
melanoma skin cancers) have metastases that are detected at the time when their cancer is 
first diagnosed. Another third of patients have metastases that are too small to be detected 
via the usual diagnostic tests. There is an inverse exponential relation for early detection 
with survival rate, and the disease can be fully cured if diagnosed early (Allard, Matera et 
al. 2004; Cristofanilli, Budd et al. 2004; Budd, Cristofanilli et al. 2006). Furthermore, for 
a patient with a malignant tumor, the surgical removal may bring immediate relief to the 
pain and suffering but leave the person with an uncertain future. The potential of remnant 
cancer cells resurgence in the body is unpredictable and there are no easy approaches to 
ascertain when it will happen again. Current methodologies that aid in the early detection 
of the disease cancer include tumor markers (such as PSA, CA 27.29, CA 15-3 and CEA) 
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and various imaging techniques. Tumor markers have little diagnostic value though they 
present well in prognosis (Zieglschmid, Hollmann et al. 2005; Elshimali and Grody 2006; 
Pantel and Riethdorf 2009), and imaging is difficult with newly formed and small 
micrometastases (Gilbey, Burnett et al. 2004). The detection of circulating tumor cells in 
peripheral blood is proposed as an alternative method in diagnosis and prognosis. 
 
The clinical relevance of assessing the quantity of CTCs in peripheral blood is to 
establish the direct association with cancer progression (Racila, Euhus et al. 1998; Allard, 
Matera et al. 2004; Cristofanilli, Budd et al. 2004; Kahn, Presta et al. 2004; Cristofanilli, 
Hayes et al. 2005; Budd, Cristofanilli et al. 2006; Hayes, Cristofanilli et al. 2006; 
Cristofanilli, Broglio et al. 2007; Nole, Munzone et al. 2007). For instance, Kahn et al. 
reported a correlation of disease stage and progression with the number of CTCs in 
peripheral blood on 123 patients (Kahn, Presta et al. 2004). Cristofanli et al. studied 177 
women with metastatic breast cancer and showed that patients with 5 or more CTCs in 
7.5 ml of blood had an overall survival of less than10 months (Cristofanilli, Budd et al. 
2004). Subsequently in a further report, they measured treatment efficacy through 
monitoring CTCs counts in blood (Cristofanilli, Hayes et al. 2005). The extraction of 
blood samples remain as one of the most commonly extracted body fluid in any health 
test which will allow ease of access to conduct CTC tests. Hence, a careful analysis of 
constituents in peripheral blood will assist in early detection of cancer. 
 
Leading technologies in CTC enrichment from blood specimen uses affinity based 
techniques which employ antibodies that are absent in blood cells.  These methods face 
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various drawbacks such as the need for pre sample preparation and more importantly the 
specificity of the antibody selected for enrichment. Additional preparatory steps are likely 
to incur CTC losses while the lack of a universal biomarker for CTC enrichment limits 
the detection of CTCs for different cancer types (Allard, Matera et al. 2004). The 
technique is also laborious, complicated and potential important information about the 
subpopulations of these cells may also be lost (Sieuwerts, Kraan et al. 2009). Furthermore, 
the isolated cells are no longer viable after processing of the blood samples which limits 
the downstream applications that can be done on CTC sub populations which hold 
important information about the metastatic process.  
 
Past studies have revealed that the shear modulus, stiffness, size and deformability of 
cancer cells (Weiss and Dimitrov 1986; Weiss 1990) are distinctively different from 
blood constituents (Shelby, White et al. 2003; Mohamed, McCurdy et al. 2004). 
Fundamental cell rheological properties of cancerous cells such as deformability and flow 
characteristics were extensively studied (Lekka, Laidler et al. 1999; Leinung, Wurl et al. 
2000; Ito, Nakanishi et al. 2002) and are attractive for CTCs enrichment. No functional 
modifications will be required as isolation is solely dependent on the biorheological 
properties differences of cancer cells and blood constituents. In addition, it bypasses the 
use of a selection antibody during the CTCs enrichment process. Without the need for 
functional modifications, it will simplify device preparation and blood processing.  
 
It is hypothesized that an efficient isolation of CTCs from peripheral blood can be 
achieved by utilizing the physical characteristics of tumor cells. From a mechanistic 
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purview, the separation and enrichment of tumor cells from blood is versatile for different 
cancer types, though significant molecular heterogeneity exists. The scope and objectives 
of the study will include designing a microfluidic device that exploits the differences in 
cell size and deformability of cancer cells to blood cells for the isolation and detection of 
CTCs. The microdevice is required to be biocompatible, and allow direct processing of 
blood to minimize intermediary steps so as not to compromise the CTC yield. In addition, 
the platform has to be able to handle large blood sample volumes and yet be gentle to 
isolated cells to maintain the integrity of CTCs. With the microdevice, the efficacy for 
separation and detection of CTCs will be studied. The system will be assessed based on 
its efficiency, sensitivity and isolation purity of tumor cells from blood. The study will 
also encompass the use of tumor cells from various cancer origins to ascertain the 
technique versatility. With clinical trials using peripheral blood specimens from cancer 
patients, it will test the applicability of the system on actual clinical samples and 





Chapter 2 Literature Review 
 
The leading cause of death in patients with carcinomas are due to metastatic lesions and 
less likely of the primary tumor itself (Pantel and Brakenhoff 2004; Gupta and Massague 
2006). Even after curative resections, the probable resurgence of the disease poses an 
uncertainty that affects the emotional aspect of the patients. Furthermore, surgical 
operations are not entirely restorative and it was reported that 20-50% of patients with 
“localized” colorectal tumors after surgical removal die of metastasis (Cohen, Kelsen et 
al. 1997; Ratto, Sofo et al. 1998; Riethdorf, Wikman et al. 2008; Sergeant, Penninckx et 
al. 2008). The need for better diagnostic, prognostic and monitoring apparatus for the 
disease cannot be over emphasized.  
 
Technology development has bring about new tools in the field of biomedical 
engineering and microfluidic devices attracted great attention for its suitability to handle 
the various challenges involved (Whitesides 2003; Toner and Irimia 2005; Whitesides 
2006). Microfluidics is still in its infancy and represents a revolution in laboratory 
innovation, bringing the benefits of miniaturization, integration and automation for 
numerous research applications. It can be considered an integrative science with a 
combination of engineering, chemistry and biology (Gomez 2008). This technology has 
been the motivation for various biochemical applications in point of care diagnostics, 
bioterrorism detection and drug discovery. For instance, the methodology has been 
applied in single cell analysis which will allow for greater discrimination of different cell 
types (Wheeler, Throndset et al. 2003; Li and Li 2005), thereby producing more sensitive 
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responses to diseases and treatment monitoring. The technology has also been applied to 
cell sorting, and produced systems with the capabilities of high throughput and rare cell 
recovery (Huang, Cox et al. 2004; Davis, Inglis et al. 2006; Nagrath, Sequist et al. 2007; 
Pamme 2007; Tan, Yobas et al. 2009).   
 
For the purpose of the discussion, the clinical significance of CTCs will be reviewed, 
showing its association to aid in studying cancer. Competing technologies for the 
detection of CTCs will also be identified and compared. Lastly, the chapter will examine 
current microfluidic systems used in cell sorting and single cell analysis which are 
relevant to the current proposed microsystem to enrich CTCs from peripheral blood.  
 
 
2.1 Clinical Significance of CTCs  
 
The detection of CTCs dates back to 1869, which was first reported by Ashworth 
(Ashworth 1869) who observed the presence of tumor cells in blood taken off from the 
saphena vein of a deceased patient. Interest on these cells in circulation amass over the 
years to address how these tumor cells traverse and survive in the blood circulation 
(Weiss and Ward 1983; Weiss and Dimitrov 1984; Weiss and Dimitrov 1986; Weiss and 
Schmid-Schonbein 1989; Weiss 1990), their clinical significance to patients’ overall 
survival rate (Pool E.H. and G.R. 1934; Roberts, Jonasson et al. 1961; Cristofanilli, Budd 
et al. 2004) and the characteristics of these cells (Paget 1889; Ashida, Okuda et al. 2000). 
The use of CTCs as a tool for monitoring and understanding tumor cells in circulation is 
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rekindled in recent years due to the availability of new and emerging technologies, and is 
progressing rapidly to address various important problems in metastasis (Pantel and Alix-
Panabieres 2007; Pantel, Brakenhoff et al. 2008). These studies outline the importance of 
understanding the cancer cell biology for CTCs and its survival mechanism for this 
diverse population of tumor cells.  
 
Several reports demonstrated important connections between the presence of CTCs in 
peripheral blood and the disease. Mostly notably, CTCs were detected in many of the 
cancers at the early stage, indicating dissemination of neoplastic cells into the 
bloodstream occur at the initial stages of the disease (Loberg, Fridman et al. 2004; 
Riethdorf, Wikman et al. 2008). The possibility for CTCs to be isolated and detected 
during the early phases of the disease may provide values in prognosis and aid to design 
regimens for more effective therapeutic treatments. A summary of various studies with 
different cancer types are presented in tables 2.1, 2.2 and 2.3. 
 
 
2.1.1 Breast Cancer 
 
Numerous studies have been put forward on the detection of CTCs from the peripheral 
blood of breast cancer patients, its clinical relevance to disease progression and overall 
survival, and a measure of treatment efficacy (Schlimok, Funke et al. 1987; Harbeck, 
Untch et al. 1994; Cristofanilli, Budd et al. 2004). Breast cancer is the most widespread 
cancer among women in Singapore and demands attention for its prevalence. Table 2.1 
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summarizes various studies utilizing different enrichment schemes for the detection of 
CTCs from breast cancer patients. The most commonly used techniques for detecting 
CTCs after enrichment from peripheral blood are immunofluorescence staining for 
specific markers and RT-PCR for different oncogenes of interest. As shown in table 2.1, 
in order to detect breast cancer CTCs, a variety of molecular markers are employed 
which include CK2, CK18, CK19, EMA, MUC5B and CEA. The detection rates also 
vary in different investigations even with trials using the same molecular markers and are 
highly indicative of the heterogeneous nature of the disease. Positive detection rates of 
tumor cells range from 18% to 83% of peripheral blood samples from cancer patients at 
various stages of the disease.  
 
Schlimok et al. (Schlimok, Funke et al. 1987) and Cote et al. (Cote, Rosen et al. 1991) 
enriched CTCs from peripheral blood using density centrifugation from a patient pool of 
155 and 49 patients, respectively. Patients who participated in the tests were from various 
stages of systemic therapy and were tested for keratins from the enriched cell populations. 
From the studies, it was deduced that the presence of CTCs in peripheral blood was an 
indication to distant metastases and was positively correlated to early recurrence of the 
disease. The clinical implications of the results show that monitoring the presence of 
these tumor cells will aid to provide a measure to disease relapse and possibly introduce 
new treatment regimens before further disease progression occurs. The results from 
various other tests (Harbeck, Untch et al. 1994; Cristofanilli, Budd et al. 2004; Becker, 
Becker-Pergola et al. 2006) further confirms the CTCs’ clinical value which present 
correlations of the quantity of CTCs in peripheral blood to overall and disease free 
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survival, and the effects of chemotherapeutic exposures to cancer patients. Becker et al. 
(Becker, Becker-Pergola et al. 2006) in their studies showed a reduction of CTCs after 
chemotherapy which proves to be useful and sensitive to gauge treatment efficacy. Given 
the heterogeneity of the disease, Berois et al. (Berois, Varangot et al. 2003) investigated a 
series of molecular markers by RT-PCR. CEA and CK19 were shown to be significant 
prognostic indicators for patients with early disease. In short, CTCs in breast cancer had 
been detected as early as during primary diagnosis and also described as potential 
measures of chemotherapeutic treatments. The persistence of CTCs in circulation is likely 
to demonstrate the link to the disease and further evidences from molecular analyses will 
elucidate the characteristics of CTCs to design targets for them. 
 
 
2.1.2 Colorectal Cancer 
 
The detection of CTCs in colorectal cancer patients has yielded significant impact to 
demonstrate its clinical benefits. Most studies were performed with cytokeratin anti-
bodies which are illustrated in table 2.1. A variety of methodologies have also been 
employed which showed clinical correlation to patients at different stages of the disease. 
For instance, Silly et al. (Silly, Samonigg et al. 1992) used 5 ml of blood extracted from 
the patients who participated in the study and showed that there were a spike in tumor 
cell detection directly after surgical operations. CTCs were also discovered at early stages 
of the disease though the numbers were small. A total of 19 patients were enlisted for this 
trial and had a 79% detection rate using CK18 as the detection marker. In a similar trial 
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that examines the effects of surgical procedures, O'Sullivan et al. (O'Sullivan, Collins et 
al. 1997) predicted a high disease recurrence with the presence of CTCs after the 
operation to resect the tumor. Flow cytometry was used to detect CTCs in the samples 
using CK18 as the detection marker. Patients involved in the study were distributed over 
different disease stages and yielding a 27% detection rate from the sample population.  
 
Broll et al. (Broll, Lembcke et al. 1996) studied the results from 34 patients using density 
centrifugation to enrich CTCs from 8 ml of blood and showed that there was a strong 
relationship between the patients and the stage of their disease. The results were 
promising given patients from different stages showed a strong link to CTC detection. A 
panel of markers was also tested specifically for colorectal cancer and had varying 
detection rates which could be specific to the etiology of cancer. A 74% detection rate 
was achieved and clearly effective to associate the severity of cancer to specific patient’s 
state of health. Cohen et al. in 2 separate investigations (Cohen, Garin-Chesa et al. 1998; 
Cohen, Punt et al. 2009) showed the importance of detecting CTCs for colorectal cancer 
patients. In an earlier study with smeared samples, a significant decline in CTC count was 
observed after the tumor was resected. In more recent analyses using the CellSearch 
system, CTC count was demonstrated to be strongly linked to overall survival of patients 
with a sample size of 397 specimens. Progression free survival was also shorter for 
patients with unfavorable CTCs count and can be used as supportive evidence for future 

















Correlation to disease Reference 
Breast 
Cancer 





>T1 37% (49) Showed early recurrence (Cote, Rosen et al. 1991) 
Lymphoprep 4-6ml EMA; Pan-CK M0,T1-4 38% (100) 
Demonstrated relapse free 
survival and overall survival 
(Harbeck, Untch et al. 1994) 
CellSearch 7.5ml pan-CK >T2 61% (177) 
Demonstrated progression free 
survival and overall survival 
(Cristofanilli, Budd et al. 
2004) 
Biocoll 10-20ml pan-CK T1-4 83% (112) 
Chemotherapy response. 24% 
detection rate after treatment. 
(Becker, Becker-Pergola et al. 
2006) 
Buffer Coat 5ml 
MUC5B, 
CK19, CEA 
T1-4 41% (46) 
Detection rate with different 
markers. MUC5B (19%), 
CK19 (41%), CEA (17%) 
(Berois, Varangot et al. 2003) 
Colorectal 
Cancer 
Ficoll 5ml CK18 I-IV 79% (19) 
Different detection rate in 
different stages. M1 (16%), 
Post operative (71%) 
(Silly, Samonigg et al. 1992) 
(Lindemann, Schlimok et al. 
1992; Panaro, Lou et al. 2005) 
Flow 
Cytometry 
NA CK18 I-IV 27% (48) 
Fewer metastatic cells 
postoperative 
Recurrence high with CTC 
present postop 





I-IV 74% (34) 
Correlated to stage of disease 
Detection rate for markers: 
CEA (30%), 17-1a (26%), 
pan-CK (67%), CK18 (52%) 




M1 34% (80) 
Showed significant decline 
post operation: resected: 9%; 
non resected: 34%  
(Cohen, Garin-Chesa et al. 
1998; Hou, Bhagat et al. 
2010) 
CellSearch 7.5ml pan-CK IV NA (397) 
Important prognostic factor 
for overall survival and 
progression free sruvival 
(Cohen, Punt et al. 2009) 




2.1.3 Lung Cancer 
 
Table 2.2 summarizes 5 different studies conducted on lung cancer patients to investigate 
the significance of CTCs for this particular cancer type. Different methods of CTC 
isolation had been employed with specimen volume used in the tests ranging from 0.5 ml 
to 20 ml of blood. A variety of markers were also tested which is clearly indicative of the 
diverse nature of the disease and showed a high success rate to determine the molecular 
characteristics of lung cancer. For instance, Maheswaran et al. (Maheswaran, Sequist et al. 
2008) demonstrated the active monitoring of changes in genotypes of epithelial tumor 
cells in circulation. EGFR mutations which are responsible for resistance to certain drug 
treatments are identified in patients with NSCLC. By actively monitoring the changes of 
secondary mutations in the tumor cells, better administering of drugs can be devised.  
 
In other tests with lung cancer patients, there were direct correlations to tumor size and 
grades. Pantel et al. (Pantel, Izbicki et al. 1993) provided affirmative evidence of CTC 
detection with the severity of cancer linking tumor size and grading to the detection of 
CTCs. A sample population of 82 specimens was tested with 0.5 to 5 ml of blood volume 
using density centrifugation. Patients were in stage I to III of the disease. The results also 
showed that the disease recurrence is also linked to the amount of CTCs detected. In 
another test with EpCAM as the detection marker, there were however no significant 
conclusions drawn with clinical outcome with CTC detection. Brunsvig et al. (Brunsvig, 
Flatmark et al. 2008) tested 196 specimens from patients with stage I-IV lung cancer and 
denoted no significant correlation. The results could be due to the unsuitability of the 
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detection marker that was used in the tests or the heterogeneity of the disease. The former 
might be a stronger reason for the discrepancy as studies which utilized cytokeratins as 
detection markers registered a strong link to the clinical outcome of lung cancer patients. 
Kasimir et al. and Yasumoto et al. (Kasimir-Bauer, Schleucher et al. 2003; Yasumoto, 
Osaki et al. 2003) in two separate studies showed that the presence of CTCs significantly 
related to reduced overall survival in lung cancer patients and is correlated to the tumor 
size. Patient sample sizes were 80 and 351, respectively in each of the investigation and 
yielded a detection rate of 23% and 32%, correspondingly. The use of CTCs in patients 
with lung cancer is thus promising to aid in active disease monitoring and prediction of 
overall survival.  
 
 
2.1.4 Prostate Cancer 
 
There is evidence that detection of CTCs in peripheral blood of prostate cancer patients 
may represent a prognostic parameter. Different molecular markers have been proposed 
such as cytokeratins, PSA and EpCAM, which has shown to be effective to a certain 
extent. Detection of CTCs in prostate cancer patients are found in early stages of the 
disease as illustrated in table 2.2 and genotyping of the cells are now possible with new 
techniques available. Oberneder  et al. (Oberneder, Riesenberg et al. 1994) for instance 
correlated the presence of CTCs to tumor size, distant metastases and tumor 
differentiation. A total of 84 specimens were analyzed with a detection rate of 33%. 
Samples were taken from patients with early stages of the disease and enriched using 
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density centrifugation with 6 ml of sample volume. CK18 was used as the detection 
marker and the results were promising in identifying patients with critical conditions. 
Melchior et al. (Melchior, Corey et al. 1997) used PSA, which is a common serum 
antigen tested in clinical practice for prostate cancer. PSA is usually low in normal 
people and a sudden elevation may suggest the presence of prostate cancer. 16% of the 
prostate cancer patients with organ confined tumors were found to be positive for PSA 
from CTCs using RT-PCR. A total of 71 participants were enlisted, showing an 
approximate 20% detection rate. Patients with advance stage disease showed 71% 
positive responses in peripheral blood. The study also demonstrated a direct comparison 
with samples from the bone marrow and presented evidence that specimens from the 
bone marrow had a significantly higher rate of detection. This is suggestive of a more 
sensitive reading with bone marrow specimens than peripheral blood.  
 
On the other hand, Pfitzenmaier et al. (Pfitzenmaier, Ellis et al. 2007) concluded there 
were no specified correlations to the disease status using EpCAM as the detection marker. 
However, a detection rate of 92% was achieved for certain subgroups of cancer patients 
that were tested, showing a strong positive outcome. The tests also claimed to achieve the 
isolation of viable cells via an immuno-magnetic separation. In another interesting study, 
Leversha et al. (Leversha, Han et al. 2009) successfully performed fluorescence in situ 
hybridization (FISH) on isolated CTCs using the CellSearch system. FISH probes used 
included AR, MYC and 8p which were shown to be present in men with progressive 
castration-resistant disease. This is beneficial to aid in understanding disease genotypes 
and active monitoring for secondary mutations so that treatment regimens can be tailored. 
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Correlation to disease Reference 
Lung 
Cancer 
Ficoll 0.5-5.0ml CK18 I-III 22% (82) 
Correlated to tumor size and 
grade. Showed disease 
recurrence with CTC detection 





10-20ml EpCAM I-IV 55% (196) 
No significant correlation to 
clinical outcome 






10ml pan-CK I-IV 23% (80) 
Presence of CK+ cells 
significantly correlated with 
reduced overall survival 
(Kasimir-Bauer, Schleucher et 
al. 2003) 
Ficoll 5ml CK18 I-III 32% (351) 
Correlated to tumor size and 
overall survival for stage II 
and III patients 
(Yasumoto, Osaki et al. 2003) 
CTC Chip 1-5ml Pan-CK; EGFR NA 100% (23) 
Monitoring changes in 
epithelial tumor genotypes 
during treatment 
Genotyping CTCs had a 
sensitivity of 92%, whereas 
plasma genotyping had 33% 




Ficoll 6ml CK18 N0M0 33% (84) 
Correlated to tumor size, 
distant metastases and tumor 
differentiation 
(Oberneder, Riesenberg et al. 
1994) 




CTCs preferential in the bone 
marrow than peripheral blood 
(Melchior, Corey et al. 1997) 
MACS 10ml EpCAM NA 46-92% (292) 
Viable cells can be acquired 
but no specific correlation was 
performed 









Performing FISH in CTCs in 
men with progressive 
castration-resistant disease to 
analyze disease genotypes 
(Panaro, Lou et al. 2005; 
Leversha, Han et al. 2009) 
* EGFR: Epidermal growth factor; PSA: Prostate specific antigen; AR: Androgen receptor 
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2.1.5 Renal Cancer 
 
Renal cell carcinoma typically has poor prognosis as early detection is difficult and for 
the lack of tumor specific markers in the disease (Loberg, Fridman et al. 2004). The 
detection of CTCs may therefore aid in the clinical setting to provide a measure for early 
detection or monitoring purposes. It is also valuable to rely on CTCs to detect specific 
mutations linked to RCC which can be used as a means of genotyping the disease. As 
shown in table 2.3, Ohlmann et al. (Ohlmann, Ozgur et al. 2006) showed that the 
expression of MN/CA9 was significantly present in CTCs from renal cancer patients. The 
sample size of 24 yielded a positive detection rate of 67%. 8-10 ml of blood were drawn 
from each patient and enriched for CTCs using centrifugation. There were however no 
direct correlation to clinical outcome with the presence of CTCs in the study. On the 
other hand, Bluemke et al. (Bluemke, Bilkenroth et al. 2009) demonstrated significant 
links of CTCs to lymph node status and showed CTCs can be a strong prognostic factor 
in RCC. 16 ml of blood were used from each patient and enriched using centrifugation 
and a negative depletion technique that removed WBCs from the buffy coat. CK8/18 
were used as the detection marker for CTCs. An interesting observation from this study 
found considerable quantity of cytokeratin negative large cells which appeared to have 
morphology and characteristics of tumor cells. This is indicative of the presence of CTC 
subgroups which were not identified with standard markers.  
 
Using the CellSearch system, Basso et al. (Basso, Rossi et al. 2009) and Zovato et al. 
(Zovato, Opocher et al. 2009) demonstrated the detection rate of 80% and 71% with a 
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sample size of 20 and 21, respectively. It was also found that the baseline CTC count do 
not significantly relate to the extension of the disease nor to sunitinib (Tryosine Kinase 
Inhibitor) response. There were however interesting observations about the state of CTCs 
in the samples which showed that 50% of sporadic RCC patients and 66% of VHL 
patients had 100% apoptotic cell population. In addition, few studies have focused also 
on the genotyping aspects of RCC. For instance, Ashida et al. (Ashida, Okuda et al. 2000) 
reported the detection of the VHL tumor suppressor gene mutations in CTCs which were 
also detected in the tumors of RCC patients. This is direct evidence of tumor shedding 
into the blood circulation with CTCs retaining the characteristics of the primary tumor. 
The clinical implications of the study showed the possibility of tracing the characteristics 
of the tumor based on the cancer cells that were released into the blood circulation. 
 
 
2.1.6 Gastric Cancer 
 
Although recent technological advances and awareness to a healthy diet have brought 
about an improvement in clinical outcome of patients with gastric cancer, the prognosis 
of patients in their advanced stages remain bleak. This is largely because of the high 
incidences of metastases and disease resurgence. Early detection is the key component to 
reduce the mortality rate. The use of CTCs in the clinical setting may provide a 
convenient technique as blood samples are readily available. With a suitable biomarker, 




For instance, Koga et al. (Koga, Tokunaga et al. 2008) tested a variety of different 
common targets in gastric cancer. The density centrifugation technique was applied to 
enrich the tumor cell population from 10 ml of blood for the trials. mRNA sequences for 
CK18, CK19, CK20 and CEA were used on the isolated cell populations to test their 
prevalence. The results showed that the CK19 and CK20 expressions were significantly 
increased in patients with a non-curative operation or recurrence of gastric cancer as 
compared to healthy volunteers. Furthermore, the five year survival rate for patients’ 
samples who expressed CK19 above the cutoff rate (results taken from healthy volunteers) 
was 50% and for CK20 was 51.9%. CK19 was proposed to be a more suitable marker 
than CEA, CK18 and CK20. This could be clinically beneficial for prognosis or to design 
a postoperative strategy of adjuvant treatment.  
 
In another investigation, Mimori et al. (Mimori, Fukagawa et al. 2008) showed that MT1-
MMP was useful to detect CTCs in the sample population of 185 specimens. A 100% 
detection rate was achieved in the trials with patients from stages I-IV. It was further 
deduced that MT1-MMP from CTCs in peripheral blood of cancer patients was an 
independent marker for determining cancer recurrence and distant metastases. These can 
be clinically valuable to make judgments about the disease and also in early detection of 
gastric cancer. In other tests with gastric cancer patients, Allard et al. (Allard, Matera et 
al. 2004) demonstrated the isolation of intact cancer cells using the CellSearch system 
with an average of 24 recovered tumor cells from the tests. A 31% detection rate was 
achieved using pan-cytokeratin as the detection marker in a sample size of 13 specimens.  
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Correlation to disease Reference 
Renal 
Cancer 
Ficoll 8-10ml MN/CA9 pT1-3 67% (24) 
Use of MN/CA9 in the 
detection of CTCs  
No direct correlation of CTCs 
to clinical outcome 
(Ohlmann, Ozgur et al. 2006) 
Ficoll + 
MACS 
16ml CK8/18 NA 41% (154) 
CTCs correlated to lymph 
node status and a strong 
prognostic marker 
(Bluemke, Bilkenroth et al. 
2009) 
CellSearch 7.5ml pan-CK NA 80% (20) 
Baseline count does not 
correlate to extension of 
disease nor to sunitinib 
treatment 
(Basso, Rossi et al. 2009) 
CellSearch 7.5ml pan-CK NA 71% (21) 
Apoptotic cell population 
found in CTCs from sporadic 
RCC patients (50%) and VHL 
patients (66%) 
(Zovato, Opocher et al. 2009) 
Ficoll 10ml VHL I-IV 75% (20) 
Mutations of the VHL tumor 
suppressor gene detected in 
CTCs which are also found in 
the tumors of RCC patients 
(Wilding, Kricka et al. 1998; 









Detection rate with different 
markers. CK19 (11.6%); 
CK20 (15.5%).  
5 year survival rate for CK19 
positive patients (50%); CK20 
(51.9%) 
(Koga, Tokunaga et al. 2008) 
NIL 1.0ml MT1-MMP I-IV 100% (185) 
MT1-MMP in peripheral 
blood was an independent 
factor for determining 
recurrence and distant 
metastasis 
(Mimori, Fukagawa et al. 
2008) 
CellSearch 7.5ml pan-CK NA 31% (13) 
Mean cell count of 24 cells 
were retrieved 
(Allard, Matera et al. 2004) 
*VHL: von Hippel-Lindau 
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2.2 Prior Art in CTC Detection  
 
The isolation, quantification and molecular categorization of CTCs is extremely 
challenging as they exist as rare events in the presence of billions of blood cells. 
Furthermore, given the sheer size of these cells, handling them using conventional bench 
top techniques are difficult. Several methods are proposed in the processing of peripheral 
blood for the detection of CTCs and a summary is outline in table 2.4. A more detailed 
analysis for two of the leading detection methodologies are presented in the subsequent 
discussion.  
 
The CellSearch system (Veridex LLC, Raritan, NJ, USA) is currently the only setup in 
the market approved by the US Food and Drug Administration (FDA) for the clinical use 
of CTCs in breast, colorectal and prostate cancer. It consists of a CellPrep system, the 
CellSearch Epithelial Cell Kit, and the CellSpotter Analyzer. Blood specimens are also 
extracted into their proprietary CellSave Preservative Tube which is an evacuated blood 
draw tube containing EDTA as the anti-coagulant together with the presence of  a cellular 
preservative. Requirements for blood specimen storage are straightforward, keeping them 
in room temperature prior to use and to be processed within 72 hrs of blood collection. 
The CellPrep machine is for the purpose of sample preparation and is semi-automated to 
ease operations. The CellSearch Epithelial Cell Kit is a set of standard reagents used for 
CTC enrichment and detection. It consists of ferro-fluids coated with epithelial cell 
specific EpCAM antibodies for immuno-magnetically separation of CTCs from 
peripheral blood; a mixture of two phycoerythrin-conjugated antibodies that bind to 
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cytokeratins 8, 18, and 19 which are supposed to be present in epithelial tumor cells and 
not in blood cells; anti-bodies for CD45 conjugated to allophycocyanin as a negative 
stain to identify WBCs; and DAPI to label the nucleus of the cells.  
 
The kit also comes with standard buffers for washing procedures, permeabilizing of the 
cells and blocking to prevent non specific bindings. Briefly, 6 ml of buffer was added 
into 7.5 ml of blood, centrifuged for 10 minutes at 800g, and placed on the CellPrep 
system. The plasma and buffer layer were then automatically removed by the system and 
ferro-fluids from the CellSearch Epithelial Cell kit were added followed by an incubation 
period. The bounded cells were the separated by means of the affinity of ferromagnetic 
beads attached to cells to be attracted to a magnetic field and the rest of the effluence 
were aspirated. The staining agents used to identify CTCs for immunofluorescence were 
added together with the permeabilization buffer and set for another incubation cycle to 
molecular interactions to complete. After the incubation period, the magnetic field was 
applied again so that cells were immobilized and excess reagents could be washed away.  
 
For the final procedure before detection, the isolated cells were resuspended in the 
MagNest Cell Presentation Device, where it contained a magnet that orient the labeled 
cells onto the same focal plane for analysis using the CellSpotter Analyzer. The 
CellSpotter Analyzer is a four-color semi-automated fluorescence microscope which 
captures images from the MagNest and presents them to the user for manual 
identification. Criteria used to confirm the presence of CTCs included round to oval 
morphology, a visible nucleus (DAPI positive), positive staining for cytokeratin, and 
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negative staining for CD45. As illustrated in table 2.4, the system had a proof of concept 
using specimens from numerous cancer patients suffering from a variety of different 
cancers (Allard, Matera et al. 2004) and were successful in providing standardized tests 
for reproducible measurements. The specificity of the technique was high and had 
negative responses from healthy volunteers. Recent development effectively integrated 
additional features for the molecular characterization of CTCs to determine the genotype 
analysis of the disease (Leversha, Han et al. 2009). The system thus has potential to be 
clinically relevant for monitoring and prognostication of cancer. 
 
Figure 2.1 shows the experimental setup for the CTC-chip which is also used to isolate 
and detect CTCs from whole blood. It consisted of an array of microposts as shown in 
figure 2.1d which had been chemically treated to be functional with EpCAM antibodies. 
The arrays of microposts were optimally positioned to enhance the interaction of tumor 
cells to micropost surface, and the microscale of the setup ensured a high surface area to 
volume ratio to maximize capture efficiency. The flow velocity was the controlling 
parameter for the efficacy of the system and to establish flow through the chip, pneumatic 
lines were added to drive sample fluid across the system.  
 
In brief, for device preparation, the microchips made out of silicon were purged with 
nitrogen and sealed using pressure sensitive adhesive tape (3M, St Paul, USA). The 
silicon chip was then placed in a custom made plastic manifold with inlet and outlet ports 
for fluid handling. The system was made leak resistant by mechanically locking the 
microchip in the manifold with screws that ensures all the parts were tightly in place. 
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Standard luer lock fittings were added to the inlet and outlet ports to facilitate sample 
entry and effluence removal.  
 
For blood delivery into the system, a pneumatic driving setup consisting of manual 
pressure regulators, digital gauges and a blood tube rocking mechanism were designed 
in-house. Prior to running the samples, the device was purged with 3 ml of buffer that 
removed trapped air bubbles in the system. The sample was then allowed to mix on the 
rocker for at least 5 min before running the experiment. At the start of blood processing, 
the pneumatic pump was turned on and adjusted to the required settings for the desired 
Figure 2.1 Isolation of CTCs using a microfluidic device. (a) Experimental setup with the 
sample continually mixed on a rocker, and pumped through the chip using a pneumatic 
pressure-regulated pump. (b) Overview of the CTC-chip with microposts etched in silicon. (c) 
Whole blood flowing through the microfluidic device. (d) Scanning electron microscope 
image of a captured NCI-H1650 lung cancer cell spiked into blood (pseudo coloured red). The 
inset shows a high magnification view of the cell. (Nagrath, Sequist et al. 2007) 
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flowrate. After the processing of blood, the microchip was flushed with 10 ml of PBS at 
10 ml/h to remove cells that were non specifically bounded.  
 
Identification and enumeration of CTCs were then performed in situ with 
immunofluorescence staining for cytokeratin, CD45 and DAPI. The microchip was 
scanned automatically in a 1mm × 1mm grid format using the programmable stage and 
Qcapture Pro software (Media Cybernetics, Bethesda, MD, USA). Enumeration for CTCs 
were then performed with careful evaluation of the images at 100X magnification by 
examining the staining results, morphological characteristics such as cell size and shape 
to exclude possibilities of non specific cells that were attached and/or debris present in 
the blood specimen. The results were evaluated by 2 different operators independently to 
reduce inter-operator variability. As illustrated in table 2.4, the proof of concept were 
shown with patients samples from lung, prostate, pancreatic, breast and colorectal cancer, 
and achieving a high sensitivity and tumor cell yield from these samples. The system was 
further proven to be gentle to isolated cells and the use of whole blood directly aid to ease 
operational needs.   
 
With the enabling technologies available, the isolation of CTCs which is clinically 
beneficial will be enhanced. Table 2.4 summarizes the main points about current 
techniques employed in the detection of CTCs but is by no means exhaustive for all the 
existing techniques. As noted in table 2.4, the capture target using different techniques 
are dissimilar but have yielded significant results with clinical samples. These 
technologies are also likely to complement each other to fill in the short comings 
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associated with certain techniques. Ikonisys (table 2.4) for instance uses a combination of 
centrifugation and filtration which is likely to reduce noise levels (non specific cells) in 
the isolated cells. Affinity based techniques using EpCAM is hotly debated as the marker 
is shown in certain cases to be less expressed in various tumor cells (Sieuwerts, Kraan et 
al. 2009), which will result in the loss of these cells and consequently presents an 
underestimate of CTCs in blood. Nonetheless, the development of techniques for CTCs 
isolation is still new and with more studies done on these tumor cells, better 
methodologies can be devised which will be clinically beneficial. The long term goal is 











2.3 Microfluidics for Cell Sorting using Physical Methodologies 
 
Effective methods for the manipulating, isolating and sorting of cells are essential for the 
development of microfluidic-based point of care diagnostic platforms. Cells are 
extremely heterogeneous, differing in their genetic makeup, behavioral characteristics 
and functions. The benefits of such technologies enable high speed processing with 
enhanced sensitivity, allowing for rare cell recovery and better discrimination of cell 
types in a mixed cell population. Microfluidic systems are well positioned to tackle the 
challenges involved, given the compatibility with biological species, similar dimensions 
to cells and accuracy in manipulation with flow control. The proposed system for the 
 
 
Table 2.5 Cell sorting using physical techniques with microfluidic devices 
Methodology Capture Target Reference 
Pillar structures that deflect 
particles and cells based on size 
Sorted beads of different sizes and fractionation of 
blood in a continuously mode 
(Huang, Cox et al. 2004; 
Davis, Inglis et al. 2006; 
Inglis, Davis et al. 2006) 
Side diffusive filter system in a 
microchannel 
Leukapheresis, for the enrichment of leukocytes in 
a blood sample 
(Sethu, Sin et al. 2006) 
Direct filter structures in the 
flow path of flow that passively 
selects fetal cells in the sample 
Isolation of fetal cells from maternal circulation 
(Mohamed, Turner et al. 
2007) 
Weir structures that have a gap 
at the top of the pillars to 
selectively allow cells to pass 
based on deformability 
Separation of leukocytes from blood and allowed 
further molecular analysis to be carried out  
(Wilding, Kricka et al. 
1998; Panaro, Lou et al. 
2005) 
Step weir structures that 
differentiate samples based on 
physical means and the gap 
distance from the top of the 
chamber   
Size separations of mixtures of 0.5 and 1.0 microm 
carboxylated polystyrene beads as well as of binary 
mixtures of Staphylococcus aureus and 
Saccharomyces cerevisiae cells and of S. cerevisiae 
and Escherichia coli cells are demonstrated. 
(Vankrunkelsven, Clicq 
et al. 2004) 
Inertia flow separation based on 
the migration of particles across 
stream lines due to the inertial 
aspect of the flow   
Massive parallelization of continuous pathogenic 
cell separation from diluted blood 





isolation of CTCs from the peripheral blood of cancer patients works on the physical 
characteristics of cancer cells from blood cells, and the section aims to review various 
physical separation microfluidic technologies. Table 2.5 highlights various examples of 
microfluidic systems utilizing physical separation to effectively discriminate against 
different cell types. 
 
 
2.3.1 Pillar structures  
 
The use of pillared structures is attractive for size and deformability based cell sorting. 
Huang et al. describe a method of continuous separation based on a “deterministic lateral 
displacement” of micron sized particles with a resolution less than 20 nm (Huang, Cox et 
al. 2004). The layout of the microfluidic device consists of arrays of pillar structures 
within the main flow channel.  
 
Using the technology, Davis et al. successfully fractionated blood components by 
tailoring the design of the microfluidic devices to the sizes of the blood cells (Davis, 
Inglis et al. 2006). In the approach, the selection mechanism is based on the size of the 
cells as they interact with the obstacles (figure 2.2a). Taking advantage of the laminar 
characteristics of the flow profile, sorting of the cells is achieved during the asymmetric 
bifurcation of the flow around the pillars. The effectiveness of the separation is controlled 
by the critical hydrodynamic diameter (Inglis, Davis et al. 2006) which is related to the 
size of the gaps, positions of the pillar arrays and the dimensions of the cells. Sizes of 
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cells smaller than the critical hydrodynamic diameter maintains an average downward 
flow direction following the streamlines around the pillar obstacles. Above the critical 
diameter, cells are laterally displaced into the adjacent streamlines in a particular 
direction controlled by the placement of the pillars.  
 
The advantage of the system lies in its simplicity and reliability. It does not require the 
presence of any molecular tags nor complex preparatory procedures and the system 
Figure 2.2 Cell separation using lateral displacement in a laminar flow. (a) Schematic of 
design and separation principle. Particles that are smaller than the critical diameter (green 
particle) follow initial designated streamlines while the larger particle (red particle) is 
displaced to the right during the interactions with the obstacles. (b) Fractionating device that 
separates blood cells. (c) Plasma separation device for the removal of all cells from whole 
blood (Davis, Inglis et al. 2006). (d) Design of microfluidic diffusive filter for leukocyte 







maintains clog free throughout various sample processing (Davis, Inglis et al. 2006). In 
addition, the microfluidic device is capable of sorting multiple sizes of cells in a single 
pass as shown in figures 2.2b and 2.2c for the fractionation of whole blood.  
 
Besides utilizing the characteristics of the laminar flow, pillar structures are ideal as 
filters for cell sorting. By tailoring the dimensions in between pillars, selection of cells 
based on their size and deformability can be achieved. The technique has been 
demonstrated to be effective in isolating circulating tumor cells (CTCs) from blood 
(Mohamed, Murray et al. 2009; Tan, Yobas et al. 2009) and also in leukapheresis (Sethu, 
Sin et al. 2006). Sethu et al. showed the ability to enrich leukocytes from whole blood 
without clogging the device and offers the possibility for the leukocyte depleted blood to 
be returned to the donor (figure 2.2d) (Sethu, Sin et al. 2006). The design features pillar 
structures with 2.5µm gaps alongside the central channel that permits passage of 
erythrocytes in a continuous separation while acting as barriers to leukocytes.  
 
With a similar methodology, CTCs which are generally larger and stiffer than blood 
constituents are impeded with different gap sizes (Mohamed, Murray et al. 2009; Tan, 
Yobas et al. 2009). The technique which is simple and straightforward is attractive for 
cell sorting in various applications. However, such physical systems that separate cells 
passively by geometrical and rheological differences are likely not universal. The gap 






2.3.2 Weir Structures 
 
Cell sorting using mechanical filtration techniques such as weir structures in microfluidic 
designs are straightforward and simple to operate. The mechanism at which separation is 
achieved is primarily by the sizes of components in a heterogeneous sample. Gaps are 
created in between weirs and the top cover, which performs as a filter to permit smaller 
cells to go through while impeding larger cells. Wildings et al. use a series of such weir 
structures to isolate leukocytes from blood (Wilding, Kricka et al. 1998) as shown in 
figure 2.3a. The weir-type filter features a 3.5 µm gap between the silicon structure and 
the Pyrex top cover, which effectively allows the passage of biconcave shaped 
erythrocytes of 7.6 - 8.2 µm diameters and 2 µm thicknesses. The major drawback of a 
direct filtration system is the clogging issues that may interfere with the separation 
(b) (c) (a) 
Figure 2.3 Physical based separation using weir structures. (a) Impediment of white blood 
cells due to the size of the cells comparing with red blood cells (Wilding, Kricka et al. 1998). 
(b) Weir structures alongside the main flow channel which effectively prevents clogging when 
dealing with larger sample volume. (c) The weir type device after filtration of blood showing 




process due to the processing of large sample volumes. Weir filters that are perpendicular 
to the flow cause cell buildup over time, leading to obstructions. Chen et al. produce 
microfluidic devices by setting weirs structures alongside to the main flow (Chen, Cui et 
al. 2008) to address the cell clogging issue as depicted in figure 2.3b. The device consists 
of 3 parallel micro channels, separated by weir filtration blocks along the main flow 
direction. With a 3.5 µm gap, the device allows erythrocytes and other smaller cells to 
cross from the main channel into the side flow, which effectively restricts only the 
leukocytes in the main channel (figure 2.3c). However, such mechanical filtration 
systems that separate cells by geometrical differences are likely not universal and will 
require variations in design when the target sample changes. Furthermore, reported 
studies show limited efficiency in the target cell isolation (Wilding, Kricka et al. 1998; 
Chen, Cui et al. 2008) though the amount is sufficient for further downstream analysis to 
be carried out.  
 
Nonetheless, physical cell separation represents a simple yet straightforward means for an 
effective separation. The use will be extended in the current study to address rare cell 
events to detect CTCs from metastatic cancer patients.  
 
 
2.3.3 Inertia Flow Separation 
 
The use of inertia forces in separation is an important technique given the simplicity of 
the procedure and is generally label free during separation. In a laminar flow as in the 
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Figure 2.4 Inertial forces that achieves self-ordering of articles. (a) Schematic of the ordering 
process. Precise ordering of initially scattered particles is observed both longitudinally along 
the direction of flow and laterally across the channel. (b) Top-down views of fluorescent 
streak where flow is from left to right. Particles are initially uniformly distributed within the 
fluid and focusing of particles into four single streamlines is observed. (c) For a symmetric 
curving channel the symmetry of the system reduces focusing to two streams. Above a critical 
Dean number (De) focusing is perturbed. (d) For an asymmetric curving system, focusing 
down to a single stream is favored. Focusing is again more complex as De increases. (e) A 
confocal cross-section of the rectangular channel shown in b shows focusing of particles to the 
four channel faces. (Scale bar, 10 μm.) (f) Schematic diagram showing the force balance 
between the shear-gradient (F shear, red arrows) and wall-induced lift (F wall, blue arrows) 
for particles in three positions. (g) Confocal cross-section for an asymmetric channel. (h) 
Starting at the inlet on the left, a random inlet distribution of fluorescent microparticles is 
focused to a tight streamline on the right after a short distance. (Scale bar, 160 μm.) (Di Carlo, 




case of fluid traversing in a microfluidic channel, it is generally accepted that in the 
absence of an external force, particles tend to follow defined streamlines. Inertia forces 
become significant when the aspect ratio and geometries of the flow channels are altered 
as characterized by Di Carlo et. al (Di Carlo, Irimia et al. 2007). By making use of the 
inertia effects, particles can cross streamlines in a predictable manner, thus achieving an 
effective separation (Di Carlo, Irimia et al. 2007; Di Carlo, Edd et al. 2008; Di Carlo, Edd 
et al. 2009; Gossett and Di Carlo 2009; Russom, Gupta et al. 2009; Hou, Bhagat et al. 
2010).  A schematic of how a series of ordered particle can be obtained due to the inertia 
forces exerted of them in the flow is shown in figure 2.4. By further controlling the fluid 
flow parameters as shown in figure 2.4b, c and d, the effects of the focused flow can be 
enhanced to attain a more distinctive separation. 
 
Using this phenomena in fluid flow, cell separation of pathogenic bacteria cells was 
retrieved from diluted blood specimens (Mach and Di Carlo 2010). A massive parallel 
microfluidic device was designed and achieves more than 80% removal of the bacteria 
cells after 2 passes. It allows a throughput of 400 million cells per minute and can process 
blood at 240 ml.hr. The technique is potentially useful in the field for its simplicity and 





Chapter 3 Methods and Materials 
 
3.1 Microdevice Fabrication 
 
Figure 3.1a highlights the fabrication steps involved in the manufacture of the 
microdevice. The microfluidic biochip was produced using soft lithography (Chang, di 
Tomaso et al. 2000) and the procedures are described as follows. The design of the 
microdevice was first printed on a photo mask (Infinite Graphics Inc., Minneapolis, MN, 
USA) which was drawn on a computer aided design (CAD) software Cadence (Cadence 
Design Systems, Inc., San Jose, CA, USA). SU8-2025 (Microchem Corporation, Newton, 
MA, USA), a negative photoresist was spin coated at 3200 rpm for 45 seconds on an 8 
inch silicon substrate to achieve the thickness of 18-20 μm. Then it underwent an 
ultraviolet exposure of 120 mJ/cm
2
 through the photo mask where the portions that were 
exposed become polymerized. Following that, the photoresist developer removed the 
unexposed region chemically. A final hard bake in the oven was performed to ensure a 
better adhesion of the photoresist to the substrate. The designs on the silicon substrate 
become the master molds (figure 3.1b) which could then be used for replica molding of 
the microdevice. 
 
Polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, Midland, MI, USA) mixed 
according to manufacturer’s recommendation (10:1) was degassed and poured over the 
master mold. The mixture was then subjected to the curing conditions of 80°C for 2 hours 
in an oven. Fluidic ports were created using punches on the patterned PDMS shown in 
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figure 3.1c after the removal from the master mold. The PDMS block together with a 
glass slide was then subjected to oxygen plasma treatment and bonded irreversible. A 
power setting of 70W, exposed to plasma for 65s with oxygen flowrate of 60 sccm were 
used. The bonded microdevice underwent a final heat sterilization cycle at 150 ºC 
overnight. Prior to use, tubings were finally inserted directly into the fluidic ports of the 
finished microdevice to allow blood samples to be introduced.  
 
 
3.2 Experimental Setup and Apparatus Preparation 
 
The experimental setup which is integrated onto an inverted microscope (Leica 
Microsystems GmbH, Germany) is illustrated in figure 3.2. The compatibility with 
Figure 3.1 Major steps in the fabrication of the microdevice. (a) Device fabrication using soft 
lithography procedures. (b) Master mold on a pre cut 8 inch wafer. (c) Microdevice removed 







existing laboratory microscope meant that real time visualization of the isolation process 
can be achieved. Predetermined pressure differentials were used to drive the samples 
across the microdevice using manual pressure regulators in the initial design layout (Tan, 
Yobas et al. 2009). The platform was upgraded as depicted in figure 3.2a to use 
compressed air from two large syringes to produce pressured lines. A program written in 
NI Labview (National Instruments, Austin, TX, USA) controlled the programmable 
syringe pump (Harvard Apparatus, Holliston, MA, USA) and made minute adjustments 
every 100 ms in response to pressure drop. The differential pressure was measured by a 
pressure transducer (Honeywell, Morristown, NJ, USA) which was feedback to the 
computer via a voltmeter to precisely control the pressure settings into the microdevice. 
This allowed semi-automation in the blood processing and also made the entire system 
(a) 
Figure 3.2 Experimental apparatus and setup. (a) Schematic of the entire setup showing the 
pressure control component and the microdevice system. (b)  Entire CTCs isolation setup 
which is integrated onto an inverted microscope to allow real time visualization and 
















easily portable without requiring external pressure sources. The control of the pressure 
differential is critical as the efficacy of CTC separation is highly dependent on the 
applied pressure conditions. With the semi-automated system, the refresh rate of 100 ms 
ensured the operating pressure differential is tightly controlled. 
  
For apparatus preparation prior to samples processing, the microfluidic system was 
flushed with 5mM EDTA (Sigma, St. Louis MO, USA) buffer through the sample inlet as 
shown in figure 3.2b for 10 minutes at 120 µl/min. No other preparatory steps were 
required for the sample.  
 
The device was mounted on an inverted microscope, with custom made fixtures as 
depicted in figure 3.3 to hold liquid reservoirs as close as possible to the microfluidic 
device to minimize sample/reagent wastage in the tubings during processing. The setup 
also allowed multiplexing of the microdevices to concurrently process more samples at 
the same time (figure 3.3b and 3.3c). The fixtures which are shown in figure 3.3a is made 
of acrylic and fabricated using a laser cutter from the Institute of Microelectronics, 
A*STAR. Dimensions of the fixtures are designed to be compatible to the existing Leica 
microscope and could be easily modified to suit other microscope systems by changing 




The complete experimental setup is shown in figure 3.2b and 3.3, and cell enumeration 
was done manually and immediately after cell isolation. Image capturing of the cell 
isolation process was taken using a high speed camera (Photron, San Diego, CA, USA). 
 
 
3.3 Computational Fluids Dynamics (CFD) Analysis 
 
A 3D computational model of the microdevice was developed to better understand the 
flow characteristics as well as to help in initial optimization of the design as shown in 




Figure 3.3 Custom made fixtures for holding tubings and reservoirs for the microdevice. The 
fixtures is made of acrylic and fabricated according to dimensions using a laser cutter to fit the 
Leica inverted microscope. (a) Overview of the setup. (b) Single unit processing. (c) Dual 


















was created using Gambit (Ansys Inc., Lebanon, NH, USA) and simulated using Fluent  
(Ansys Inc., Lebanon, NH, USA) as illustrated in figure 3.4c. The model consisted of 
fourteen isolation structures. An optimized mesh density of 579, 820 was used. Mesh 
independence was ascertained by increasing the mesh density and observing the 
difference in velocities to be less than 1%. Adopting a no-slip wall boundary condition 
and fluid properties of pure H20 (density at 998.2 kg/m3 and viscosity 0.001003 kg/ms), 
the study was carried out by analyzing the velocity profiles, particle flow paths and shear 
Figure 3.4 Isometric views of the computational models for the optimization of the 
microdevice isolation structures. (a) Overview of the device layout generated from Gambit. 
(b) Closeup view of the cell isolation structure compartment. (c) Simplified model for the 
analyses of shear stresses around isolated cells, flow profile around the isolation structures and 
optimization of structure positions.  
(a) 
(b) (c) 
CTC isolation regions 









stresses at the isolation structures under different initial conditions. Boundary conditions 
at the inlets were determined experimentally by measuring the flow rates through the 
device at various operating pressures. The simulated operating pressures range from 2kPa 
to 20kPa. Free stream was assumed at the outlet.  
 
This is crucial to ensure minimal damage to the isolated cells. The shear stresses and flow 
patterns in the microdevice at various operating conditions were extracted from the 
computational analysis to aid in optimizing the design and determining the operating 
conditions for the microdevice.  
 
 
3.4 Blood Collection 
 
Informed consent from healthy volunteers and cancer patients were taken before blood 
extraction, as approved by the institutional review board. Blood samples from healthy 
patients served as controls and were also used in spiking experiments for the 
characterization of the microdevice. Samples were stored in EDTA tubes (BD, Franklin 
Lakes, NJ, USA) prior to use and discarded after the experiment. From cancer patients, 9-
10 ml of blood was extracted each time with the first 0.5-1.0 ml of blood discarded to 
prevent false positive responses. A total of 10 healthy volunteers and 39 cancer patients 





3.5 Cell Culture  
 
The cell lines of human breast adenocarcinomas (MCF-7 and MDA-MB-231), colorectal 
adenocarcinoma (HT29), gastric carcinomas (AGS and N87), hepatocellular (HepG2 and 
HuH-7) adenocarcinomas, tongue squamous carcinoma (CAL27) and pharynx squamous 
carcinoma (FADU) were used to characterize the efficacy of the microfluidic chip. 
Culturing of cells was done in 25 cm
2
 tissue culture flasks (Greiner Bio-One, 
Frickenhausen Germany). AGS and N87 were maintained using RPMI 1640 (Sigma, St. 
Louis, MO, USA) while the rest used Dubelcco’s Modified Eagle Medium (DMEM) 
(Sigma, St. Louis, MO, USA). Both culture media were supplemented with 10% fetal 
bovine serum (FBS) (Hyclone, Logan, UT, USA) and 1% penicillin G / streptomycin / 
amphotericin (Gibco, Carlsbad, CA, USA).  
 
The culturing media were continually changed every 2 days during the maintenance of 
the cancer cell lines, keeping the cells with fresh media which supported their growth. 
Upon close to 95% confluence in the flask, the cells were sub-cultured and the protocols 
are as follows. Cells were washed with 1×phosphate buffered saline (PBS) to remove 
traces of media in the culturing flask and 2.5 ml of trypsin-EDTA (Gibco, Carlsbad, CA, 
USA) was added. Trypsin-EDTA aided to release the cells from the culture flask surface 
so that these adherent cells become suspended. The culture flask was then placed back 




Confirmation of cell detaching from the surface of the flask was done optically under the 
inverted microscope using phase contrast imaging at 10X magnification. An additional 
2.5 ml of fresh media was added into the suspended cells mixture to neutralize the effects 
of trypsin-EDTA. The cell suspension was then spun down into a pellet using 
centrifugation at the operation parameters of 1200 rpm for 5 minutes. The supernatant 
was removed and fresh media of 1 ml was added to resuspend the cell pellet. Depending 
on the cell type, a minimum seeding number was replaced into a new flask based on the 
recommendations from the American Type Culture Collection (ATCC). The rest of the 
cells were used for experimentations.  
 
 
3.6 Cell Size Measurements and Spiked Sample Preparation 
 
The measurement of cell diameters is important for the study, as the separation technique 
uses the physical characteristics of cancer cells to enrich them from peripheral blood. For 
cell size measurements of the cancer cell lines, the diameter was taken as an average 
reading obtained from images of 100 suspended cells and determined using an image 
processing software (NIS-Elements AR, Nikon Corp., Singapore). For the preparation of 
sample solutions used in the various experiments, cancer cell counting was done with a 
disposable hemocytometer (iN Cyto, Republic of Korea) and serial diluted to achieve the 




For a more detailed description, in each experiment involving cancer cell lines, cells were 
grown to confluence and resuspended in culture media. A portion of the suspended cells 
were taken as control in the experiment and cultured normally. The rest was diluted to a 
concentration of approximately 100 cells per milliliter and the sample solution was 
injected into the device for characterizing the isolation efficiency of cancer cells. For cell 
viability experiments, isolated cells were retrieved by reversing the pressure differential 
in the system which directed the isolated cells to dislodge and flow towards to the 
collection point. The collected solution was centrifuged at 1200 rpm for 5 minutes with 
the cell pellet resuspended later in culturing media DMEM. These were then reseeded in 
the T25 culture flask. Their proliferative rates were compared with normal cultures which 




3.7 Immunofluorescence Staining to Identify CTCs  
 
To ascertain the isolation purity, each of the cancer cell types were added into whole 
blood donated from healthy donors at a concentration of approximately 100 cells per 
milliliter. The sample solution was further diluted with 5mM EDTA in a 1:2 ratio to 
reduce the sample viscosity so that it could be processed easily. Isolated cells in the 
microdevice were immunofluorescently stained to distinguish between cancer cells and 
hematopoietic cells to allow the visual examination of the isolation purity of cancer cells 




For the control experiment, the pre-mixed sample of blood and cancer cells (200 μl) was 
incubated onto a 12 mm coverslip (polylysine coated) for 30 minutes. The sample was 
then stained for EpCAM (1:50, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) to 
identify cancer cells, CD45 (1:50, Santa Cruz Biotechnology Inc. , Santa Cruz, CA, USA) 
for white blood cells and 4',6-diamidino-2-phenylindole (DAPI) to permit nuclei 
visualization. 
 
For staining in the microdevice, a pressure differential of 5 kPa was used to induce fluid 
flow into the microdevice. The value of 5 kPa was chosen as it best preserves the state of 
the isolated cells in the microdevice as compared to using higher pressure differentials. 
Lower pressure conditions would increase the processing time. Captured cells were first 
fixed by flowing 4% paraformaldehyde (PFA) for 30 minutes, permeabilized by 0.1% 
Triton X-100 in 1 PBS for 10 minutes, followed by washing with 1PBS for 15 minutes 
and adding 10% goat serum to block out non-specific bindings. To identify cancer cells, 
0.2 ml of EpCAM antibodies were injected for 15 minutes,  left to stand for another 45 
minutes and followed by washing with PBS. The procedures of antibody injection and 
PBS wash were repeated for the secondary antibody (1:500, goat anti-mouse AlexaFluor 
568, Invitrogen Corp., Carlsbad, CA, USA).  For the identification of white blood cells, 
0.2 ml of fluorescein isothiocyanate (FITC) conjugated with CD45 antibodies were 
injected for 15 minutes, left to stand for another 45 minutes and followed by washing 
with PBS. Staining was completed by flowing DAPI for 15 minutes at 5 kPa followed by 




For the identification of CTCs in metastatic lung and nasopharyngeal cancer patients, 
anti-cytokeratin antibodies (CAM5.2, BD Bioscience, San Jose, CA, USA) were used. 
For renal cell carcinoma (RCC) patients, anti-panCytokeratin antibodies (1:50, Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA) were used. A positive CTC count was 
defined to be cytokeratin positive, CD45 negative and DAPI positive. 
 
 
3.8 Experimental Tests with Low Cancer Cell Count 
 
We attempted to ascertain the detection limit for the setup with low cell count in sample 
solutions. 1-3 cell(s) were suspended in 1ml of 1×PBS and passed through the device. 
Isolation of individual cells from suspended state after trypsinization was done by either 
manually pipetting or using the fluorescence activated cell sorter (FACS, BD FACSAria 
II Cell Sorter, Franklin Lakes, NJ, USA) to automatically sort the cells.  
 
For each trial with different cancer cell lines, a sample size of 10 experiments was 
adopted. The study was conducted with cancer cells from diverse origins to ascertain the 
universality of the isolation and detection technique. The device was prepared normally 
as illustrated in section 3.2 and freshly trypsinized cells from cultures were used. For 
manual picking out of cells, a drop of suspended cancer cells (highly diluted) was 
observed under the microscope and picked up using a pipette. This was then transferred 
immediately into the inlet reservoir of the system and processed by the biochip. Manual 
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pipetting is preferred over serial dilution as errors associated with the latter technique are 
enormous when dealing with low concentration of cells. FACS is another alternative 
which provided a faster means to obtain small number of cells per sample. The sole issue 
of the automated technique is the errors involved to get a single cell per vial and the 
correct transfer of the sample to the reservoir. Potential significant errors in sample 
preparation were minimized by confirming the presence of cells under the microscope 
before transfer to the inlet reservoir. 
 
 
3.9 Blood Processing Protocol 
 
The average blood processing time for 2 ml of blood was approximately 3.5-4.0 hrs, 
inclusive of a washing step to remove blood residues from the system. Detailed step by 
step procedures for the clinical aspect are illustrated in figure 3.5. As stipulated in the 
instructions from the institutional review board, informed consent was taken under no 
forms of undue influence. Procedures for blood extraction were described earlier in 
section 3.4 and blood processing was performed preferably within 24 hrs. Depending on 
the requirements of the clinical collaborators, a cell count and/or extraction of CTCs were 






1. Fix all connections 
2. Buffer flushing at 120 µl/min for 10 minutes 
Figure 3.5 Flowchart that shows the sequence of events from requesting for informed consent 




Chapter 4 Microdevice Design and Computational Fluid 
Dynamics Simulations 
 
4.1 Microdevice Design 
 
Figure 4.1 shows the experimental setup and the design of the microdevice. The 
microdevice is affixed to custom made fixtures as shown in figure 4.1a which aids to 
compact the system and allows it to be portable. In this way, the usage of reagents such 
as anti-bodies can be minimized, thereby saving cost. During processing, blood 
specimens are pressure driven into the microdevice as shown in figure 4.1b, and 
controlled by the computer, achieving a semi-automated operation. Blood enters the 
Figure 4.1 Microdevice setup and design layout. (a) Apparatus setup. (b) Microdevice chip 






























microdevice via the sample inlet (figure 4.1c), pass the cell isolation region and out from 
the waste collection at the bottom. The cell collection and secondary waste ports are 
closed at this point to prevent specimens from entering and are only activated when 
required. A set of pre-filters shown in figure 4.1c before the isolation traps also serve to 
prevent large clumps or debris from clogging up the setup and are linked to the waste 
outlet to effectively remove debris. Clogging prevention is important to get a feasible 
system which is a major issue associated with devices that attempt to separate and isolate 
cells through direct physical means (Mohamed, McCurdy et al. 2004; Di Carlo, Wu et al. 
2006; Pamme 2007). In addition, the microdevice allows for recovery of cells in the 
isolation traps through the cell collection point. A key advantage of using microfluidic 
devices lies in their laminar flow characteristics, making the profile predictable. The flow 
patterns inside the small enclosed volume can be easily controlled by changing the 
external conditions to guide the recovery of isolated cells.  
 
The technique for the enrichment and isolation of CTCs utilizes the differences in 
physical characteristics of tumor cells and blood constituents. Physical parameters such 
as the size of cancer cells and their deformability are distinctively dissimilar (Weiss and 
Dimitrov 1986; Weiss 1990; Shelby, White et al. 2003; Mohamed, McCurdy et al. 2004). 
The design of each trap follows a crescent shape with gaps of 5μm in each of the traps as 
shown in figure 4.2 to ensure the exit of blood constituents due to their ability to traverse 
very small constrictions. Multiple arrays of these crescent-shaped isolation traps are 
created in the microchannel to isolate cancer cells while allowing blood constituents to 
sieve through (figure 4.2). In this way, larger white blood cells (WBCs) of comparable 
58 
 
dimensions to but more deformable than cancer cells can be effectively removed and this 
will ensure high purity of trapped cancer cells. Each trap is positioned with a pitch of 50 
μm which effectively prevents cells build-up in any particular region. In addition, each 
row of isolation structures is offset by 25 μm to enhance the hydrodynamic efficiency 
(figure 4.2). The crescent shape of the isolation trap which is alternated left and right also 
aid to prevent clogging and allow each structure to hold a single cell by directing 
incoming cells away, as the fluid resistance on the adjacent sides are smaller when the 


















Figure 4.2 Design characteristics and view of fabricated device for CTCs trapping. (a) 
























































































































































































































































Furthermore, the isolation traps are divided into 6 compartments as shown in figure 4.3c, 
spanning over two sections that facilitated the maximal retrieval of isolated cells. During 
cell retrieval, the rounded inverted crescent-shaped structures provide a favorable path in 
the opposite flow direction to enable the cells to be extracted out to the cell collection 
point (a thorough computational study is presented in section 4.2). It also minimized 
physical interactions as the laminar streamlines curves around the structures to reduce 
possible mechanical damage during retrieval. For each microdevice, there are a total of 
900 isolation structures.   
 
A detailed schematic of the microdevice design is presented in figure 4.3. The overall 
size of the microdevice spans 5.1 by 3.7 mm as shown in figure 4.3a. Reservoirs (figure 
4.3b) are tapered and rounded in shape to minimize air bubbles and dead volume during 
the injection of fluids into the microdevice. The system is divided into various 
compartments and separated into 2 sections as depicted in figure 4.3c. These effectively 
help to maintain similar flow conditions throughout the microdevice, ensuring a smooth 
cell retrieval path and also aid in enumeration of isolated cells. The uniform array of 
isolation traps in the design as shown in figures 4.3e and 4.3f further enhance the cell 
counting process and will facilitate digital image analysis for process automation. To 
increase hydrodynamic efficiency to ensure better cell isolation, rows of isolation traps 
are offset from each other to make certain that cells that escape the initial traps will more 
likely enter traps in subsequent rows. Lastly, the design has a set of pre filters before the 
cell isolation region (figure 4.3d) that aims to hold debris or larger particulates and 
prevents them from entering the isolation traps. These large foreign matters are potential 
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problems if they enter the cell isolation region and will likely clog up the system. The 
design of the microdevice allows a direct and instantaneous means of removing large 
particles trapped in the pre-filters by manipulating the flow conditions and sending them 
out through the adjacent waste port which is connected to the left side of the inlet (figure 
4.1c). Miniaturized systems are particularly susceptible to issues such as clogging and 
trapped bubbles which will limit its reliability (Pan 2004), and these are taken into 
consideration during the designing phase of the microdevice.  
 
 
4.2 Design Considerations and Computational Fluid Dynamics (CFD) Simulations 
of Flow Parameters 
 
The purpose of the computational study is to ascertain flow parameters as well as 
optimize the isolation trap design for better efficiency. A crescent shape with two 5 µm 
gaps was chosen as the final design for the isolation trap due to various considerations. 
Pillared structures which are ill designed have the tendencies for lateral collapse (figure 
4.4b) (Schmid and Michel 2000). The failure modes are closely linked to the material 
properties of the polymer and the dimensions of the structures (Hui, Jagota et al. 2002; 
Sharp, Blackman et al. 2004). Equation 4.1 highlights the conditions that will result in the 

















Here, E* ≡ E/(1 - v2) is the plane strain modulus of the PDMS block, where E is the 
Young’s modulus and v is the Poisson’s ratio of the material. Furthermore, γs is the 
surface energy of the material, and a, w, and h are the dimensions of the features’ width, 
spacing, and height, respectively as shown in figure 4.4a. The reliability of the system 
will be highly dependent on the pillar size and the gap between them as depicted in 
equation 4.1. Failure can occur due to capillary forces from the retained solvents on the 
structures during the cleaning cycle of the PDMS before bonding, which are sufficiently 
large enough to cause them to contact during air or blow drying. Contact can also occur 
during improper peeling from the master mold. Once contact occurs, pillars may adhere 
to each other as a result of surface adhesive forces as shown in figure 4.4b. This renders 
the microdevice unusable and will have an effect on the process reliability for the 
 
Figure 4.4 Failure modes of pillared structures. (a) Schematic of adjacent pillars sticking to 
each other (Hui, Jagota et al. 2002). (b) Left: Collapse of pillars in an earlier microdevice 
design after a washing cycle. Right: SEM image of epoxy nanopillars collapsing on its own 
weight (Zhang, Lo et al. 2006). 
(b) 






production of the biochips. The design of interest for the isolation trap has a w/a of 2.5 
and an aspect ratio of approximately 4 for the height to width of the structures. γs is taken 
as 21.6 ergs/cm
2
 for PDMS as reported by Chaudhury and Whitesides (Chaudhury and 
Whitesides 1991). 
 
Another design consideration that will affect the reliability of the microdevice fabrication 
is the possibility for the collapse of the top surface of the PDMS which is termed roof 
collapse by Sharp et al. (Sharp, Blackman et al. 2004).  Equation 4.2 puts forward the 
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Here σ is the uniform stress applied to the top of the PDMS block, E
*
 is the plane strain 
modulus defined earlier and a, w, h are dimensional parameters depicted in figure 4.5. 
The instability is a direct result of the soft characteristics of the polymer and large 
unsupported region in the design. Emmanuel et al. (Delamarche, Bernard et al. 1997)  
demonstrated that if the aspect ratio is too large, the microchannels can collapse even 
under its own weight (Delamarche, Schmid et al. 1997). Henceforth, the considerations in 
the current design of the microfluidic chip minimize such large areas. This is also a key 




be introduced. This facilitated a straight forward means for the scale up of the current 
design to allow more samples and cells to be trapped.  
 
In order to understand the flow profile around the irregular shaped structures and 
ascertain minimal damage on the isolated cancer cells due to hydrodynamic forces, the 
fluid velocity and shear stress profiles were simulated for the operating pressure 
differentials applied. A 3D model was used in all the simulated conditions and the results 
from the mid plane of the model were extracted. Figure 4.6 depicts the velocity patterns 
and flow path surrounding the cell isolation structures at a maximum operating pressure 
of 15 kPa which is likely the critical case in this investigation. The simulated conditions 
during cell isolation (forward flow direction) and retrieval (backflow direction) were 
analyzed. This allowed a measure to estimate the effectiveness of the design before actual 
prototyping which is time consuming and laborious. Computational methods are also cost 
 
Elastomer 
Figure 4.5 Collapse of the top surface between two supporting regions in a patterned polymer 
(Hui, Jagota et al. 2002; Sharp, Blackman et al. 2004). 
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effective as numerous designs can be tested by merely generating the model and running 
the analyses. By examining the streamlines and particle paths in the model, a gauge of the 
cell isolation efficiency of the setup can be predicted, assuming a perfectly rigid particle 
in the flow.  
 
In isolating cancer cells (figure 4.6a), the gaps in the isolation traps facilitated the entry 
of the cells as shown by the path lines. These path lines were derived from simulated 
particles placed in the microdevice as they passed through the cell isolation regions. This 
was evident from the computational study showing successful interactions of free flowing 
cells in the flow with the isolation structures, which would ensure that cells that were 
Figure 4.6 Computational analyses of the flow and shear stress around the isolation structures 
at the operating condition of 15 kPa. (a) Velocity profile when isolating cells taken at mid-
plane (10 µm from the base) of the model. (b) Velocity profile during the retrieving of 
























larger and less deformable to be impeded.  Flow velocities were also much lower near the 
isolation structures which translate to lower shear stresses for an isolated cell. During the 
sample processing phase, the flow paths were actively changed as more of the traps were 
occupied. Cells began to favor adjacent sides of occupied traps (figure 4.7a) due to lower 
fluid resistance and the flow paths were diverted to prevent a local build up of cells. This 
averted the possibility of clogging in the microdevice and allowed a smooth processing of 
the blood specimens.  
 
For the purpose of cell retrieval, the flow direction was reversed (figure 4.6b) by applying 












Figure 4.7 Computational analysis of the flow and shear stress around the isolation structures 
at the operating condition of 15 kPa when the traps are occupied. (a) Velocity profile and 
simulated particle tracks. (b) Shear stress acting on a spherical cell model when the cells were 









accomplished by switching the pressure settings on the computer controlling the pressure 
lines to achieve an instantaneous change in the flow conditions in the microdevice. 
During cell retrieval, the inverted isolation structures enabled a streamline profile around 
the crescent shape isolation traps as shown in figure 4.6b. Cells that were dislodged from 
the structures were immediately pushed towards the region in between the traps which 
had a lower fluid resistance. That minimized obstruction of the cells on the recovery 
route and was less likely to get wedged in between traps. These would ensure a high 
percentile of cell retrieval in the collection outlet.  
 
In order to make certain that the system was gentle to cells in the microdevice, the 
average wall shear stresses on isolated cells subjected to a constant flow were 
characterized. This was to prevent excessive forces which could be damaging to the cells 
or altering many of its signal transduction responses (Papadaki and Eskin 1997; Haier, 
Nasralla et al. 1999; Hodgson, Kohn et al. 2000; Chang, Chang et al. 2008; Liang, 
Slattery et al. 2008). A simulated condition using 15 kPa is presented in figure 4.7b. It is 
noted that the regions of high shear stresses occur near the surface of the isolated cells 
and the structures. The average wall shear stresses on the cells due to the fluid flow are 
tabulated to establish that it did not exceed physiological conditions. Contrasting with the 
physiological wall shear stresses experienced in large arteries (10-70 dynes/cm
2
) (Malek, 
Alper et al. 1999), the estimated average shear stress around the isolated cells due to the 
flow were much lower as shown in figure 4.8. The wall shear stress acting on an isolated 
cell was predicted to be between 1.8 Pa to 5.3 Pa, corresponding to 5 kPa and 15 kPa 
respectively for the pressure differential driving the fluid in the microdevice. This 
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indicated a low possibility that cells would be affected as a result of the interactions of 
the flow and the small enclosed volume in the system. Cell integrity was likely to be 
maintained whilst in the microdevice, providing the opportunities to examine and analyze 
these rare cells in peripheral blood to understand the disease better.  
 
 
4.3 Feasibility Studies 
 
The concept of cell isolation using physical characteristics of cancer cells on a 
microfluidic device was tested with a macro setup by means of ideal rigid beads of 45 µm 
Figure 4.8 Effects of input pressure on the estimated wall shear stress of an isolation cell 




(Polystyrene Polybead® Microspheres, Polysciences Inc., Warrington, PA, USA). This 
was to ascertain that the design parameters used in the simulations were effective. 
Furthermore, the trials were used to confirm several other design considerations such as 
reduced pitch size between isolation traps, reduced row separation distances and ensure 
failures modes like lateral collapse of pillars and roof collapse of top PDMS surface do 
not occur. The various experimental design layouts extracted from the photolithography 
mask drawing are shown in figure 4.9. Six different configurations were tested for its 
Figure 4.9 Feasibility studies designs. (a-e) Evaluation of the placement of isolation traps and 
traps density per unit area. (f) Evaluation of compartmentalized design.  
(a) (b) (c) 
(d) (e) (f) 
Reduced pitch size 
between isolation traps 












isolation efficiency using rigid polystyrene beads that simulated the presence of cells in 
the samples. The size of the isolation traps were scaled up by a factor of 2 from the 
optimal layout simulated in the computational analyses and designed to be suitable to 
hold particles between 40-55 µm in diameter. This is analogous to the use of 
dimensionless analysis to predict the responses. A plastic mask (Infinite Graphics Inc., 
Singapore) was employed in the photolithographic process given that the features sizes of 
the trial designs were significantly larger with critical dimensions of 10 µm. Fabrication 
of the master mold and casting of PDMS microdevices were similar to the steps described 
in section 3.1. The sole difference was in the use of SU 8 2050 instead of SU 8 2025 
which was recommended by the manufacturer for a more uniform photoresist layer of 50 
µm.  
 
A PDMS replica mold for testing the reduced separation distance between isolation rows 
(figure 4.9d) is shown in figure 4.10a. The design consisted of a single chamber with 102 
isolation traps set out in a uniform array. Six different arrangements of the microdevice 
were put forward in the trial to confirm the simulation results experimentally. 
Standardized samples with concentration of approximately 1000 microbeads per milliliter 
of 1×PBS solution were used. Figure 4.10b shows the experimental results from one of 
the designs in a typical run. Within 20 minutes, almost all the isolation traps were 
occupied which indicated a fast loading capacity in the microdevice and likely an 
effective means to hold cells which were stiffer and significantly larger than the gap size 
in the crescent shape traps. It was also observed that single bead trappings were prevalent 
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in all the tests conducted for this particular design as demonstrated in figure 4.10b.  This 
is coherent with the design considerations set out in section 4.1 that the occupied 
isolation traps direct incoming particles to subsequent traps which would prevent a local 
build up of particles and clog up the system. It was also evident from the study that a 
large blood sample volume could be processed on this platform with minimal risk of 
failure due to obstruction of blood constituents in the microdevice. The single bead per 
trap is also useful to aid enumeration and analyses, as compared to alternative techniques 
which have isolated cells in clusters in physical traps or far apart on anti-body coated 
substrates (Mohamed, Turner et al. 2007; Nagrath, Sequist et al. 2007; Mohamed, Murray 
Figure 4.10 Feasibility study design using a scale-up version of the microdevice. (a) SU 8 
master mold for PDMS replica molding. (b) Micro beads loading showing high isolation 








et al. 2009; Kuo, Zhao et al. 2010). Having cells in clusters make distinction and exact 
counting difficult, while cells that are too far apart are laborious during counting and risk 
increased human random errors. Furthermore, a general observation from the study 
showed that initial capture rates were high when all or most of the isolation traps were 
unoccupied. There were significant bead losses when approximately 50% of the traps 
were engaged. This was a consequence of diverting incoming particles to the next 
isolation row when the earlier isolation traps were occupied. As more of the traps became 
taken, it increased the probability of a non engagement and allowed the bead to be 
washed away.  
 
In terms of fabrication issues, no roof collapsed were encountered which indicated that 
the design was overall stable. There was however slight lateral collapses of the crescent 
shape isolation traps which occurred during bonding when a force was applied to form a 
complete seal of the PDMS block to a glass slide after the oxygen plasma treatment. The 
 
 
Table 4.1 Microdevice isolation efficiency using 45µm rigid beads in the feasibility experiments  





1 Design 1 10 65.24 0.34 
2 Design 2 9 75.24 0.54 
3 Design 3 10 68.28 0.27 
4 Design 4 10 77.67 0.67 
5 Design 5 10 78.70 0.55 




problem was overcome by controlling the applied force after numerous practices. Table 
4.1 summarizes the results for the isolation efficiency of rigid beads of 45 µm in the 
microdevice for all the trial designs. The choice of using the 45 µm beads is due to the 
design of the traps that ensured an optimal fitting of the bead in the crescent well. The 
experimental spilt considered various placement issues of the isolation traps as well as to 
ascertain the stability in a compartmentalized design. A maximum isolation efficiency of 
78.7% was attained from the designs with the lowest being 65.2%. Using a Student’s t 
test, the isolation efficiency obtained from design 5 was significantly higher than designs 
1 and 3, with p < 0.05 but no significant conclusions with designs 2 and 4. However, it 
was observed that there was a higher chance of a localized build-up of beads when the 
separation distances between the rows became compacted due to the difficulties of the 
Figure 4.11 Feasibility study using 45 µm beads. Image captured at approximately 100fps. 
Scale bar represents 20 µm. 
Frame 1 Frame 3 Frame 5 





rigid beads to move in the much confined region, which ruled out the selection of design 
4. With no statistical significance between designs 2 and 5, the selection criteria reviewed 
the space requirements and decided on design 2 as it conserved about 10% less space. 
Results from design 6 were also promising that will enable scaling up of the platform by 
simply stacking or arranging in uniform array for each of the isolation chambers into a 
single microdevice. This will speed up sample processing or cater for the isolation of 
more cells which may be present. An illustration of the isolation route is depicted in 
figure 4.11 which showed a smooth entry of the bead into the trapping structures and was 
consistent with the particle tracks derived from simulation studies.  
 
It was estimated from computational analyses that the wall shear stresses acting on the 
particles were within the physiological range of forces experienced by blood cells in 
circulation. Confirmation tests were conducted by analyzing the behavior of cancer cells 
in the microdevice which provided an instantaneous means of verifying the cell integrity. 
It was observed that cancer cells were able to adhere and spread near the isolation 
structures. Trypan blue exclusion tests established that the isolated cells were viable and 
most of the cells remain unstained. Figure 4.12 shows a 2 day culture of the isolated cells 
directly in the microdevice. MCF-7 was used in the experiments and pressure driven into 
the microdevice. The flow was left stationary for approximately 1 hr for cells to attach to 
the surface before a gentle washing cycle using culturing media to remove any residue. A 
control with normal culture was used to compare the proliferation rate of the cells. The 
microdevice and the control culture were then left in a CO2 rich (5%) incubator (Thermo 
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Electric Corp., Singapore) overnight. From figure 4.12, it is shown that proliferation of 
the cancer cells are not hindered after passing through the microdevice. The outcome 
indicated that the system was gentle during the process of cell isolation and less likely to 
damage the cells with the pillars in the microdevice. To sum up, the experiments depicted 
the bio compatibility of the biochip and that negligible external forces are exerted on 
these cells in the device.  
 
In brief, the feasibility studies demonstrated the successful and efficient isolation of rigid 
polystyrene beads. The isolation trap arrangement presented in design 2 (figure 4.9b) was 
Control 
Device 
Day 1 Day 2 
Figure 4.12 Cell integrity after the isolation process in the microdevice. Control experiments 
are obtained from normal cultures and proliferation of cancer cells are assessed in the 
microdevice. Scale bar represent 20 µm. 
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selected as the finalized configuration for its advantages of lesser space requirements and 
being effective to isolate the beads. The investigation also verified certain design 
considerations such as achieving mostly single bead trapping without clogging the system. 
The platform was also determined to be gentle to cells during sample processing which is 













Chapter 5 Microdevice Characterization   
 
The characterization of the microdevice is of paramount importance to achieve the 
optimal setting for CTC isolation. Earlier discussions presented the design and feasibility 
studies of using a microfluidic device for this function. To sum up what has been put 
forward thus far, the system utilizes the biorheological differences in the cell size and 
deformability of cancer cells to achieve an effective separation.  
 
For blood processing operations, the sample is pressure driven through the system from 
the sample inlet past the cell traps and the effluence is collected in the waste outlet. The 
pressure control allows instantaneous manipulation of the fluid conditions in the 
microdevice. Each of the microdevices has 900 crescent shaped isolation structures 
formed into a uniform array where cancer cells being generally larger and stiffer than 
blood cells will be retained. The design of the traps also prevents build up of cells when 
the structures are occupied, unlike most direct filtration methods and allows processing of 
large sample volumes. Due to the rarity of CTCs in peripheral blood, processing of larger 
volumes of samples is desired and the laminar flow around the cell traps channel cells 
away to prevent clogging due to lower fluid resistance on the adjacent sides. In addition, 
each trap is likely to hold only a single cell and this simplifies enumeration either 
optically or through an image processing software.  
 
The clinical benefits of enumerating CTCs in peripheral blood have been widely reported 
(Beitsch and Clifford 2000; Gogas, Kefala et al. 2002; Hoon 2004; Budd, Cristofanilli et 
78 
 
al. 2006; Hayes, Cristofanilli et al. 2006; Cristofanilli, Broglio et al. 2007). This method 
is also minimally invasive as compared to traditional biopsies. The number of CTCs in 
blood is directly associated with the disease progression and can help in evaluating 
cancer treatment efficacy (Nole, Munzone et al. 2007). Thus, it is important to have a 
high cancer cell isolation efficiency for the microdevice to count these rare cells in blood 
specimens accurately. Our approach draws mainly upon the highly deformable nature of 
erythrocytes (Shelby, White et al. 2003) and leukocytes (Liang, Liu et al. 2005) that 
enable these cells to traverse capillaries as small as 2-5 μm whose cell diameters can 
range from 8 to 25 μm. On the other hand, cancer cells are more likely to be arrested in 
capillaries of similar dimensions (Weiss and Dimitrov 1984). Henceforth, the gaps in the 




5.1 Cell Size Measurement 
 
From table 5.1 which included measurements taken from cancer cell lines of various 
origins, it was noted that there existed a diverse range in terms of the dimensions of these 
cells. Figure 5.1 shows the cells that were just resuspended after cell culture which 
clearly highlighted the differences. Furthermore, it was observed that the morphology and 
appearances of these cells differs. At the molecular level, the genetic makeup of these 
cells is largely dissimilar due to different mutations which can explain their different 
behaviors. Hence the heterogeneity of the disease is an important factor to consider in the 
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study. For the current work, we aim to demonstrate the use of a microfluidic device using 
purely physical differences of cancer cells to isolate them from blood specimens. It is 
hypothesized that the technique is versatile to handle tumor cells from diverse origins 
though the molecular aspects of these cells are heterogeneous. The isolation rate and 
capture purity are of interest as these parameters dictates the accuracy of the tests which 
is to be associated to the state of health of the patient. Sensitivity of the microdevice to 
small numbers of tumor cells in peripheral blood is of paramount importance as well in 
the tests and we hope also to show the detection limit of the proposed platform. 
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Figure 5.1 Cancer cells in suspension for measurements of cell diameters. (a) MCF-7. (b) 
MDA-MB-231. (c) HT-29. (d) AGS. (e) N87. (f) HepG2. (g) HuH7. (h) CAL27. (i) FADU. 
Scale bar represents 20 µm 
(a) (c) (b) 
(d) (f) (e) 
(g) (i) (h) 
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5.2 Cancer Cell Isolation Efficiency 
 
For characterizing the cell isolation efficiency, low concentration of cancer cells (100 
cells per milliliter) spiked in 1PBS is injected into the microdevice at various pressure 
differentials. Small numbers of cancer cells in the sample solution mimic the rarity of 
CTCs in peripheral blood. By visually counting the number of trapped and escaped 
cancer cells, the efficiency of tumor cell capture can be determined using equation 5.1 
where a ratio of the trapped cells are taken, over the total number of cells that enters the 
microdevice. Visual inspection is preferred to minimize random errors that might occur 
during serial dilution leading to discrepancies in cell concentration in the solution. This is 
especially critical when dilution is performed to obtained very low cell counts and visual 












   
 
The main factor affecting cell isolation efficiency is the pressure applied as the input 
values directly alters the flow conditions in the microdevice. With a larger applied 
pressure differential to drive the sample solution, flow rates will increase leading to a 




deformation on cells to be able to pass through the gaps in the crescent shaped wells 
which will compromise on the efficiency for cell capture. Although, higher flow rates 
meant lesser sample processing time, the larger shear forces on the cells are undesirable 
as they can cause cell behaviour modifications due to mechanical activated signal 
pathways or cell death (Chang, Chang et al. 2008). In this investigation, the selected 
pressure differentials included 5 kPa, 10 kPa and 15 kPa which are comparable to 
physiological conditions and verified using computational analyses in section 4.2.  
 
Figure 5.2 shows the successful arrest of MCF-7 breast cancer cells and HT-29 colorectal 
adenocarcinoma in the isolation structures. Consistent with the observations from the 
feasibility tests, mostly single cells were loaded in each of the traps. It was also noted that 
(a) 
Figure 5.2 Cancer cells isolation in the microdevice which presented mostly single cell per 
trap. (a) MCF-7 (breast adenocarcinoma). Red arrows indicated regions where more than 1 








despite the diverse range of dimensions existed between different cell lines or even 
within the same cell line, the platform was able to hold them in place. The single or 
doublet cells arrested in each isolation trap facilitated cell counting with ease. For traps 
holding more than 1 cell, they were generally observed to be of smaller diameters than 
others as depicted in figure 5.2a with the red arrows. The outcome is expected as excess 
space with small cells in the traps is able to accommodate another. It can be resolved by 
tuning the trap size to suit the dimensions of the tested sample. This aspect is 
advantageous for the system as controlling the size of the traps can potentially allow the 
microdevice to be used for a wide variety of cells and applications in single cell studies. 
In addition, the experiments demonstrated that these cancer cell lines differ significantly 
in their ability to deform as well. For instance, MCF-7 (figure 5.2a) cells in the traps 
showed certain amount of deformation into the gaps in each of the cell trap that were 
meant to allow blood constituents to pass through, while HT-29 cells (figure 5.2b) 
remained perfectly spherical in the isolation structures under the same flow conditions. 
This is indicative of dissimilar physical characteristics and that HT-29 is stiffer than 
MCF-7 cells.  
 
Using the computer to control and maintain the pressure differential in the system, the 
quantitative analyses from comparing cell isolation efficiencies at various pressure 
settings is plotted in figure 5.3. In the current study, 9 dissimilar cell lines from 6 
different cancer types were used to ascertain the microdevice characteristics. A total of 
264 experimental runs were performed for the entire investigation, showing an 
approximate effective isolation rate of 80% for the tested samples, at an operating 
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condition of 5 kPa. The Student’s t-test verifies that isolation efficiencies at 5 kPa are 
significantly higher (p<0.01) for all 3 samples than at higher pressure inputs as illustrated 
in figure 5.3. It was also noticed that a downward trend was experienced as the pressure 
differential increased. The reduction in cell capture efficiency can be accounted for by the 
dislodgement of the arrested cells due to increased hydrodynamic forces acting on these 
cells at higher pressure differentials or the forcing of smaller cells through the gaps in the 
crescent traps. At the pressure setting of 5 kPa, the microdevice was capable of 
MCF-7 MDA-
MB-231



























Figure 5.3 Cancer cell isolation efficiency for various cancer cell lines in the microdevice 
over a range of operating pressure applied. Hypothesis testing was performed comparing 






































processing samples at 0.71 ml/hr with a high isolation efficiency needed for an accurate 
diagnosis. A typical experiment with the isolation of CAL27 is shown in figure 5.4.  
 
From the time sequence images extracted from the high speed camera (figure 5.4), it can 
be clearly observed for cells that try to enter an occupied trap will be pushed downwards 
to engage an empty one. This mechanism allowed single cell trapping to occur and 
prevented a local build-up of cells that might clog up the system.  
 
Other leading techniques to enrich cancer cells from peripheral blood have efficiency 
ranging from 20% to 90% (Allard, Matera et al. 2004; Lara, Tong et al. 2004; Balic, 
Dandachi et al. 2005). However, there are also numerous restrictions and complex 
preparation procedures. For example, there is limited purity when detecting low 
concentrations of CTCs (Smirnov, Zweitzig et al. 2005) in peripheral blood and various 
preparatory steps such as centrifugation, incubation and functional modifications which 
can be tedious and time consuming. The proposed microdevice is comparable to other 
Figure 5.4 Time sequence images showing the capture of a cancer cell. The arrangement of 
the cell traps enables the capture of cells that circumvent occupied traps and prevents clogging 
in the microdevice. Images taken with a high speed camera at 1000fps. 
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leading biochemical techniques in terms cancer cell enumeration from blood and is done 
without any functional modifications. The results favor the lower input pressure of 5 kPa 
to effectively isolate cancer cells given the Student’s t-test with a significance level of 
0.01 confirmed that isolation efficiencies at 5 kPa were significantly higher than other 
operating pressures for all the samples. Single cell trapping is also affirmed in our studies 




5.3 Cancer Cell Isolation Purity 
 
The cell isolation efficiencies of the microdevice were performed with pure spiked 
samples of cancer cells in 1×PBS to minimize random errors that would occur in the 
presence of blood. With blood samples, it was difficult to count the number of escaped 
cancer cells due to the presence of large amounts of blood constituents. Henceforth, the 
cell isolation efficiency and the capture purity were characterized in separate experiments.  
 
With cancer cells spiked into blood samples from healthy volunteers, the quantitative 
analyses for the isolation purity could be determined. Spiking concentrations of 100 
cancer cells per millilitre of blood which was further diluted in 5mM EDTA buffer (1:2) 
were used in all the tests. EDTA buffer was used in place of PBS to prevent blood 
coagulation. Standard staining protocols were then followed in the identification of 
cancer cells from the isolated cell population in the microdevice.  
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Figure 5.5 Live visualization of the isolation of MCF-7 breast cancer cells in a spiked blood 
sample of approximately 1% hematocrit. Red arrows indicate the passage of blood cells in the 














Figure 5.5 shows the live capturing process of MCF-7 breast cancer cells spiked in a 1% 
hematocrit blood sample taken at the input condition of 5 kPa. The blood sample was 
deliberately diluted from 50% hematocrit to 1% to permit clear visualization for 
demonstration purposes and spiked samples used in the characterization of the capture 
purity of cancer cells in the system was performed with approximately 15% hematocrit as 
stated in the preparation process in section 3.7. From the images extracted off the live 
video capture, it was observed that blood constituents passed through the structures with 
ease given their highly deformable nature. It was also evident that a build-up of blood 
cells due to the presence of the structures in the flow path was negligible and processing 
of 3 ml of sample solution was smooth. As denoted earlier and observed from the 
experiments, the cell traps held mostly single cells and was occasionally having a doublet, 
were coherent with the earlier tests for the isolation efficiency of the microdevice. This is 
also shown in figure 5.5 where the trap with an initial occupied small cell allowed the 
entry of another cell.   
 
For the isolation purity characterization, in order to differentiate between hematologic 
and cancer cells, immuno-fluorescence staining of the isolated cells was carried out. It is 
reported that the EpCAM is over-expressed in human carcinoma (Osta, Chen et al. 2004; 
Baeuerle and Gires 2007) which makes this an ideal marker to identify the cancer cells. 
All the selected cell lines in this study (MCF-7, MDA-MB-231, HT-29, FADU, CAL27, 
AGS, N87, HepG2 and HuH7) had been reported to be positive for EpCAM (Flieger, 
Hoff et al. 2001; Di Paolo, Willuda et al. 2003; Pauli, Münz et al. 2003; Osta, Chen et al. 
2004; Yamashita, Budhu et al. 2007; Joka, Pietsch et al. 2009; Wenqi, Li et al. 2009) and 
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were confirmed in control experiments. In addition, DAPI was used to counterstain the 
cell nucleus to identify all peripheral blood mono-nucleated cells (PBMC). CD45, a 
trans-membrane glycoprotein is expressed among hematologic cells and will be used to 
distinguish white blood cells (WBCs). 
 
Figure 5.6 shows the immuno-fluorescence staining results of a typical experiment for the 
isolated cells in the microdevice. The individual reagents were added into the system via 
pressure differential that drive fluid into the microdevice. A stationary holding time 
allowed the antibodies to bind to the isolated cells so that a distinction could be made. A 
positive cancer cell count for this investigation were identified using red (EpCAM 
Control 
Staining in the microdevice 
Figure 5.6 Isolation purity of tumor cells in a spiked sample using the microdevice. Immuno-
fluorescence staining to detect cancer cells using DAPI(blue) to counterstain the cell nucleus, 
CD45(green) for hematopoietic cells and EpCAM(red) to detect tumor cells. (a) Control was 
done with a mixture of blood and resuspended cancer cells. (b) Staining in the microdevice is 
to distinguish between the different cell types. Scale bar represents 20 µm. 





positive) and blue fluorescence (DAPI positive) while hematologic cells are identified 
using green (CD45 positive) and blue fluorescence (DAPI positive). This is clearly 
depicted in the control experiment in figure 5.6a. The first picture (left) shows the blue 
channel which highlights all PBMCs. The second pictures shows the presence of WBCs 
using CD45 (green) and the third picture shows cancer cells using EpCAM (red) in the 
population of PBMCs. The last picture depicts a merged view of all the coloured 
channels that highlights the positions of the cancer cells and the WBCs in the same image.  
 
For the isolated cells in the microdevice, the staining protocols was repeated and figure 
5.6b shows that high purity can be achieved, with the absence of WBCs (no visible green 
fluorescence) in the isolated cells. In the same view, it was observed also that the 
expression levels of EpCAM in the cells vary quite significantly, even within cells from 
the same cancer cell lines. The deduction was also confirmed in the control experiments 
with cells showing different level of fluorescence (different degree of brightness) which 
underwent the same processes for staining. This is likely to have an impact in the 
identification of CTCs from cancer patients as it might be difficult to recognize cells with 
low expression levels, leading to false negatives. Sieuwerts et al. (Sieuwerts, Kraan et al. 
2009) also presented evidence that EpCAM is unsuitable on breast cancer cell given the 
large diverse expression patterns and called for new anti bodies to be adopted. 
Nonetheless, the cell lines used in the investigation had been confirmed with the presence 
of the antibody and would have minimal impact on the characterization experiments.  
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Figure 5.7 shows the cancer cell capture purity in the experiments over the range of 
operating pressures applied. A mean isolation purity of 89% was obtained at the 
operating pressure of 5 kPa and showed insignificant variations at larger operating 
conditions. A Student’s t-test performed on each individual cell line showed no 
significant differences in the mean isolation purity over the range of operating pressures 
at p<0.01. The tumor cell purity in each of the tests was maintained over the entire 
pressure range. Cell isolation purity was calculated as the ratio of cancer cells to the total 
number of cells isolated from the blood mixture as illustrated in equation 5.2.  
MCF-7 MDA-
MB-231
























Figure 5.7 Cancer cell isolation purity for various cancer cell lines in the microdevice over a 
range of operating pressure applied.  
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The results were also significantly higher than leading techniques which claimed a 
separation purity of approximately 50% using biochemical means (Nagrath, Sequist et al. 
2007).  The insignificant change of capture purity over a wide range of applied pressure 
differentials and a mean capture purity of above 85% is indicative that the physical 
properties of cancer cells are distinctively different from blood constituents. The results 
also highlighted that the microdevice was effective to remove blood constituents. The gap 
size of 5 µm in each of the crescent traps was sufficiently large enough to allow blood 
cells to deform through while holding the cancer cells effectively.  
 
 
5.4 Microfluidic Chip Versatility with Cancer of Different Origins 
 
For the characterization of the microdevice, a diverse range of cancer cell lines were used 
to determine the versatility of the technique to handle different cancers as the disease is 
genetically heterogeneous (Braun, Hepp et al. 1999; Reya, Morrison et al. 2001; Shah, 
Mehra et al. 2004; Sergeant, Penninckx et al. 2008). A total of 9 different cancer cell 
lines from 6 different origins were utilized as denoted earlier to ascertain the microdevice 
characteristics. Table 5.2 summarizes the maximum cell isolation efficiencies obtained in 




interval is also calculated for each of the individual cell isolation efficiencies to gauge the 
degree of uncertainty around the mean estimates. For the current tests, the isolation of 
HepG2 proved to be the most effective with an isolation efficiency of 87.4%.   
 
Comparing across the different sets of experimental trials with different cell lines, the 
spread of the data was small as denoted by the standard deviation of each sample. This is 
likely to indicate that the results are consistent and the technique is reliable in isolating 
cancer cells from peripheral blood at the particular pressure setting which is applied. 
With a 95% confidence interval, the deviation from the mean showed little variations and 
Table 5.2 Maximum isolation efficiency and corresponding cell capture purity in the 









MCF-7 81.5 ± 5.6 [78.7%   84.3%] 87.1 ± 9.0 
MDA-MB-231 80.9 ± 5.3 [77.6%   84.2%] 85.3 ± 5.0 
HT-29 85.4 ± 4.6 [82.7%   88.1%] 90.6 ± 7.0 
AGS 78.9 ± 8.0 [73.9%   83.9%] 89.9 ± 9.0 
N87 80.7 ± 7.6 [76.0%   85.4%] 90.3 ± 7.7 
HepG2 87.4 ± 5.8 [83.8%   91.0%] 88.3 ± 7.5 
HuH7 81.1 ± 4.4 [78.4%   83.8%] 90.8 ±7.9 
CAL27* 81.6 ± 8.6 [76.3%   86.9%] 86.8 ± 10.3 
FADU 80.6 ± 8.7 [75.2%   86.0%] 90.0 ± 8.9 
* Measurements taken at the operating pressure of 3 kPa 
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constantly above 73%, which can be inferred that a high cell isolation efficiency is 
probable when the operating pressures are optimized. Furthermore, it showed that the 
technique is suitable to achieve a precise measure for each of the cancer cell lines in 
peripheral blood which is required for an accurate assessment of the state of health of 
metastatic cancer patients. Collectively, an average cell isolation efficiency of 82.0% was 
obtained with the results acquired from all the cancer cell lines. A 95% confidence 
interval of the mean cell isolation efficiency of the system was between [82.3%  83.7%]. 
This is indicative of an accurate platform for the processing and detection of tumor cells 
in peripheral blood of cancer patients as cell yield is high. Comparing across different 
cell lines, the sample standard deviation for the cell isolation efficiencies was 
approximately 2.6% which is suggestive of a rather small spread of data. The results 
showed that the system fluctuates very little across different cancer types and can be 
versatile to handle cancer cells from different origins. Furthermore, it can be inferred that 
physical properties of cancer cells remained distinctly different from blood cells across 
different cancer types, though they may differ considerable at the genetic level. These 
made separation via size and deformability of cancer cells an attractive method which 
will also resolve numerous issues surrounding affinity based separation.  
 
 
5.5 Conditions of Isolated Cells and Cell Retrieval 
 
The main aims of the system are to provide a direct means of detecting tumor cells from 
peripheral blood which will also keep cells viable so that downstream analyzes can be 
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supported. This is because the conditions of cancer cells after isolation are of interest, as 
these tumor cells in circulation are likely to be responsible for the progression of the 
disease cancer. For this aspect, preserving the native state of the cells after isolation will 
help to determine their exact nature and allow a detailed study of CTC sub-populations 
such as in the investigation of cancer stem cells which are reported to be critical to 
progressive disease (Reya, Morrison et al. 2001; Wicha 2006). This will hopefully 
elucidate clearer the metastatic process to aid in diagnostics, prognosis, monitoring and in 
the search for new therapeutic targets. 
 
Figure 5.8 shows the isolation paths of MCF-7, MDA-MB-231 and HT-29 cells into each 
of the single traps. Results from other cell lines were similar as well and hence the data 
were not shown. Cell isolation followed rather similar tracks as denoted in the CFD 
simulations and met with little resistance from the physical structures created from 
PDMS. The simulated data also presented that the wall shear stress acting on isolated 
cells were within the physiological range which meant fluid shear forces acting on these 
cells were minimized. To ascertain the deductions experimentally, the isolated cells were 
retrieved from the cell traps in the microdevice and cultured under normal conditions.  
 
Retrieval of the isolated cells in the microdevice can be achieved by altering the flow 
conditions inside the microdevice, using the valve connections and the computer which 
controls the pressure lines. Firstly, the waste reservoir was cleared to prevent backflow of 
waste materials, followed by closing of the sample inlet fluidic port. The valve leading to 
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Figure 5.8 Time sequence images to isolate a cancer cell from a spiked sample. (a) MCF-7 
cells taken at 2000 fps at the operating pressure of 5 kPa. (b) MDA-MB-231 cells taken at 110 
fps at the operating pressure of 2 kPa. (c) HT-29 cells taken at 2000 fps at the operating 






outlet and cell collection point quickly increased to 20 kPa. Isolated cells would then be 
dislodged as shown in figure 5.9 for the 3 cancer cell lines mentioned earlier. The 
returned path did not hinder the disengagement of cells from the cell traps and most of 
the events were instantaneous. Recovery of cells following the release from the traps 
were smooth as the inverted isolation structures directed the free floating cells to the 
adjacent sides and not restricting their movement. An exception in the experimentations 
lies in HuH 7 (hepatocellular carcinoma cells) where it was observed that cells’ 
dislodgement from the traps posed an issue. This is highlighted also in table 5.3 which 
showed that HuH 7 had the lowest recovery rate comparing with all the cell lines tested. 
The recovery rate is calculated based on the number of cells that are dislodged to the 






Number of dislodge cancer cells




The probable reason for the lower successful recovery rate is due to the strong adherence 
of the cancer cells to the glass substrate and the PDMS structures. This is an inherent 
property of the cell and differs in strength between different cell types. In order to remove 
them from the structures, it will require a force larger than 20 kPa for the recovery 
settings. Otherwise, chemical agents like trypsin-EDTA (0.25%) can be used to release 
them from the adherent state, before the activation of the cell recovery protocol. A larger 




Frame 1 Frame 3 Frame 5 
Frame 7 Frame 9 Frame 11 
Frame 1 Frame 6 Frame 11 
Frame 16 Frame 21 Frame 26 
Frame 1 Frame 6 Frame 11 




Figure 5.9 Time sequence images to retrieve a cancer cell from the isolation traps. (a) MCF-7 






permanently affect the cells’ biochemistry (Patton, Menter et al. 1993; Chang, Chang et 
al. 2008) or even kill the cells (Brooks 1984). Another alternative is to block the interior 
of the microdevice with a surfactant such as polyethylene glycol (PEG) or pluronic acid 
F-127. These were reported to be effective to prevent cell adhesion on coated surfaces 
(Miqin, Desai et al. 1998; Boxshall, Wu et al. 2006) and yet had minimal effects on the 
viability of the cells when used at low concentrations (negligible toxicity effects). 
However, this incurs additional preparatory steps which will increase the total processing 
time per sample.  
 
Table 5.3 Recovery rate of isolated cells from the microdevice by exerting a back flow to 
collect the cells in the collection point 
Cancer Cell 
Line 
Recovery Rate (%) 
95% Confidence 
Interval 
Deviation from the 
mean (p value)* 
MCF-7 94.9 ± 8.0 [92.1%   97.7%] 0.03499 
MDA-MB-
231 
97.3 ± 2.6 [96.4%   98.2%] ≈ 0.00000 
HT-29 96.0 ± 4.4 [94.5%   97.5%] 0.00002 
AGS 94.4 ± 5.1 [92.6%   96.2%] 0.01253 
N87 94.1 ± 7.4 [91.5%   96.7%] 0.08513 
HepG2 92.4 ± 9.7 [88.9%   95.9%] 0.45543 
HuH7 72.0 ± 13.2 [67.3%   76.7%] ≈ 1.00000 
CAL27 96.0 ± 6.4 [94.0%   98.0%] 0.00028 
FADU 92.5 ± 7.9 [89.7%   95.3%] 0.41834 
*Hypothesis testing performed with null hypothesis H0: µ=92.2 and H1: µ>92.2. 92.2% is the mean recovery rate 
for all the cell lines. 
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All the other cell lines were successfully recovered with high yields as shown in table 5.3. 
An average recovery rate of 92.2% was attained from all the cell lines, indicating a 
significant cell quantity that can be collected from the microdevice after the isolation 
process. A 95% confidence interval for the average cell recovery for this sampling was 
92.2 ± 5.1%. The spread of the data measured by the standard deviation was 
approximately 7.7% which was largely attributed to the heterogeneity between the 
different cells lines in terms of the adhesion strength to the microdevice. MDA-MB-231 
breast adenocarcinoma cells showed the best recovery rates from the microdevice and 
coincidently had also the lowest value for standard deviation. The results were indicative 
that the adherent properties of MDA-MB-231 cells were relatively weaker than the other 
cell lines tested which made it easy to be removed under the same extraction conditions. 
A Student t-test was performed on each individual cell line comparing the recovery rate 
with the mean value from the entire group. This clearly differentiated the groups which 
showed some of the cell lines faced less difficulties in recovery. For instance, with a 
significance level, α of 0.05, we reject the null hypothesis (refer to table 5.3) for MCF-7, 
MDA-MB-231, HT-29, AGS and CAL27. It is statistically significant to claim that this 
group of cancer cell lines showed a higher recovery rate comparing with the mean 
retrieval quantity.  
 
The integrity of the isolated cells was measured by the behavior of the retrieved cells 
under normal culturing conditions. It is hypothesized that the cells initiating tumors have 
stem cell like properties (Marx 2007) and CTCs being circulating in bloodstream are the 
potential targets. Isolating sufficient living CTCs have been a challenge with limited 
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success (Pantel, Brakenhoff et al. 2008) mainly due to the harsh conditions that were 
subjected to the cells in the body before it was retrieved. Current leading techniques do 
not suffice to maintain the quality of these cells and an optimal culturing condition needs 
to be further examined (Kaiser 2010). Removing isolated cells in the proposed 
microdevice for further analysis could be achieved with ease by altering the flow 
conditions to induce the cells to flow towards the cell collection point. The process of cell 
recovery was repeated for 5-8 cycles to obtain enough cell number and the retrieved cells 
were then reseeded to a culture flask. A normal culture from the same batch was 
concurrently maintained that served as a control for comparison.   
 
Figures 5.10, 5.11 and 5.12 illustrate an overview of a 5-day culture for MCF-7, MDA-
MB-231 and HT-29. Similar conclusions were also obtained for the rest of the cancer cell 
lines that were tested. The proliferative rates of reseeded cells were compared to normal 
cultured cells to ascertain that isolated cancer cells were not affected by the microdevice. 
Initial seeding of cells was approximately similar in all experiments and can be verified 
by observing the cultures at day 1. Comparable initial cell numbers were observed on the 
control and experimental culture flasks at day 1. Cells were then allowed to grow for 5 
days with a medium change every 2 days. Over the same duration, there were no 
observable differences in proliferation rate for all cell-lines as shown in figures 5.10, 5.11 
and 5.12 when compared to their respective normal cultures. The morphology of the 
retrieved cells and its control experiment were also rather similar. For instance, reseeded 
MDA-MB-231 (figure 5.11) showed a spindle shape trait which was coherent with the 






























































































































































































































































































































































































































































































































































































which were also exhibited in the control experiments. This uniformity in cell behaviour 
confirmed that the retrieved cells were unaffected after isolation in the microdevice and 
that the system was gentle during the processing. 
 
  
5.6 Microdevice Detection Limit 
 
The rarity of CTCs in the presence of a multitude of blood cells is the main technical 
challenge to identify them. The ratio of CTCs to blood cells can be of a billion orders of 
magnitude difference which implies a high noise to signal ratio in the pre-processed 
specimen. An enrichment step is thus crucial and a sensitive setup is desired to detect 
small numbers of cells in the mixture. Therefore, the detection limit of the system is of 
interest as it represents the sensitivity of the microfluidic chip in CTC detection. For 
these experiments, very low counts of cancer cells were added to 1×PBS, either with 
manual pipetting or FACS, and made to pass through the microdevice. It is noted that 
manual pipetting is a laborious and unreliable procedure which will not always yield the 
collection of one single cell. The cell number can vary between 1 to 5 cells but this can 
be clearly observed under the microscope. Using the FACS on the other hand is a 
straightforward process but errors associated in the separation can be quite high when 
trying to obtain a live single cell in each sample from our observations. As the separation 





We used 1-3 cells in each of our experiments to mimic the rarity in the specimen and 
determine the detection limits of the platform. All other experimental procedures are 
similar to that used in establishing the microdevice cell isolation efficiency as illustrated 
in section 5.1. We define a positive ratio for the number of trials for which at least one of 
the total number of cells spiked into PBS is retrieved, over the total number of cases. A 
value closer to 1 denotes most of the trials were successful to recover the cells while a 
lower value illustrates the converse situation. This provided a gauge of the detection limit 
for the microdevice with respect to each of the cell lines. A total of 90 experimental runs 




Table 5.4 Isolation efficiency and positive ratio for low cancer cell count using 
spiked (1-3 cells) samples. 
Cell Line Cancer Type 
Sample 
Size, n 










































To sum up, the mean positive rate achieved from the investigation was approximately 
0.81 from all the nine different cancer cell lines. The results were promising to indicate 
an average success rate for 8 out of every 10 tries in detecting low cell counts from the 
specimens using the proposed microdevice. This was also coherent with the microdevice 
efficiency characterizations in section 5.1 which predicted an average isolation efficiency 
of 80%. However, within cancer cells of the same origin, it was observed that there 
existed distinct isolation rate variations. For instance, MCF-7 was found to have a higher 
positive detection rate at low cell numbers in the sample solution than MDA-MB-231 
which was of the same cancer type. This could be attributed to a number of factors such 
as the heterogeneity of different cancer cell lines, random errors in FACS separation 
when preparing the spiked sample or a result of the setup with cancer cells adhering to 
tubes before entering the microdevice. From the diverse range of cell lines tested, MCF-7 
and HuH7 showed a perfect detection process with all positive responses from each tests. 
On the other spectrum, N87 and CAL27 fared poorly in the study with a detection rate of 
0.6 and 0.68 respectively. Nonetheless, an overall effective rate of 81% is hopeful and 
significant enough to accurately detect CTCs with high sensitivities from the peripheral 












The enrichment of CTCs in peripheral blood using the microdevice is based on cell size 
and deformability differences, with the assumption that CTCs are generally larger and 
much stiffer than blood constituents. In this way, as the mixture of cells passes through 
the isolation regions in the microdevice as shown in figure 6.1, cancer cells will be 
impeded by the physical cell traps while blood cells passes through with ease. With a 
uniform array of 900 crescent shaped cell isolation structures optimally positioned, the 
isolation efficiency was maximized for the detection of CTCs and fully characterized 
with techniques illustrated in chapter 5. For the microdevice, it processes whole blood 
directly to isolate CTCs, which simplifies operations and experimental preparation. No 
prior work is required to modify the blood specimen which makes it attractive and 
straightforward. Various features are also built into the device to ensure the smooth 
processing of blood, such as pre-filters, compartmentalized isolation regions and the 
ability to retrieve isolated cells.  
 
 
6.1 CTCs in Patients with Renal Cell Carcinoma (Kidney Cancer) 
 
In this study, we seek to demonstrate the isolation of CTCs in peripheral blood of renal 
cell carcinoma (RCC) patients using purely CTCs’ cell size and deformability differences 
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Figure 6.1 Overview of the microdevice during the processing of whole blood directly for the 
isolation and detection of CTCs. The images were extracted from a real time video taken at 60 
fps of the procedure using a 5× magnification lens on an inverted microscope. Scale bar 
represents 100 µm. 
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from that of blood cells. Patients with RCC have a high probability of haematogenous 
metastasis (Weiss, Harlos et al. 1988; Pagano, Franzoso et al. 1996) and disseminated 
tumor cells from the bone marrow of RCC patients have demonstrated a strong 
prognostic value (Buchner, Riesenberg et al. 2006). By applying biorheological 
differences in cell separation such as that of the cell dimensions and ability to deform, it 
bypasses the need for a selection antibody during the CTCs enrichment process. 
Furthermore, the lack of a suitable universal tumor marker for diagnosis or monitoring 
for RCC (Loberg, Fridman et al. 2004) limits the efficacy of the affinity based separation 
technique. In addition, Allard et al. (Allard, Matera et al. 2004) reported low sensitivities 
in CTC detection using the Cell Search system with EpCAM as the selection marker on 
patients with renal cancer They hypothesized that the heterogeneity in the expression 
levels of EpCAM on CTCs’ surfaces causes variations in the ability of the system to 
recover and detect these cells. Our approach is thus attractive as it is a label free method 
to effectively isolate CTCs from blood, and cells that are generally larger and stiffer will 
be retained. The system being gentle to the isolated cancer cells is likely to maintain the 
integrity of these cells.  
 
Here, the device processes whole blood directly without the need for intermediate 
preparation, thus minimizing potential cell losses as shown in figure 6.1. Biochemical 
functional modifications are also not required for the microdevice which simplifies 
device preparation. Also in the design for a smooth operation, the pre filters in the 
microdevice are necessary to block out large clumps or debris which can come from the 
blood specimen or the fluidic connections of the microdevice from entering the cell 
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isolation region (figure 6.1). This is required to ensure that the tests are not hindered due 
to blocked isolation traps from the large clumps.  
 
Furthermore, the compartmentalized isolation regions aids in the overall support of the 
microdevice as noted in section 4.2 and make certain that the flow characteristics are 
uniformly distributed across the microfluidic channel. The uniform array of the isolation 
traps facilitated cell enumeration in situ and allows processing of large blood sample 
volume (in the range of millilitres) in a microscale device. Contrary to direct filtration 
methods where clogging is an issue, this microdevice directs incoming cells from 
occupied isolation traps to the next row of unoccupied traps, thus preventing potential 
build up of cells in a particular region, which has been demonstrated in chapter 5 using 
spiked samples.  
 
In addition, the optical transparency of the microdevice enables the use of 
immunofluorescence to detect CTCs in situ. The detection of CTCs using 
immunofluorescence staining is performed directly on the microdevice which ensures 
maximum cell yield and minimizes the usage of expensive reagents.  
 
For this investigation, blood samples of RCC patients are examined using this 






6.1.1 Blood Sampling of Metastatic Renal Cancer Patients and Control Experiments from 
Blood Extracted from Healthy Volunteers 
 
Ten healthy volunteers and 32 RCC patients participated in the study after informed 
consent were taken as approved by the institutional review board. Blood samples from 
healthy volunteers serve as control experiments to ascertain the microdevice accuracy. In 
all, 99 peripheral blood samples were extracted from 32 RCC patients from the National 
Cancer Center, Singapore between June 2009 to February 2010. 9 – 10 ml of blood are 
extracted from every patient each time with the first 0.5 – 1 ml of blood discarded to 
prevent false positive responses. Samples were stored in EDTA tubes (BD, Franklin 
Lakes, NJ, USA) prior to use and most blood samples were processed within 24 hours 
after extraction.  
 
 
6.1.2 Linearity of Circulating Tumor Cell Detection 
 
In order to determine a suitable amount of blood volume and measure the variability for 
the tests, we analyzed the first 10 blood specimens taken from RCC patients and varied 
the volume of blood processed. This is important from the considerations on both the 
patient’s comfort level for the amount of blood drawn and the operation time to process 
the sample. Minimizing the amount of blood required per test is advantageous as the 
emotional burden is reduced for the patient and may further aid to convince future test 
subjects to participate in the trials to use CTCs as a monitoring tool for their disease. This 
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is also likely to minimize dropout rate as the level of discomfort from the tests are 
minimal. On the operations, optimizing the quantity of blood in each test will help to 
decrease the blood specimen processing time. This will be beneficial in maintaining the 
conditions of CTCs by reducing the exposure time of these cells to fluid shear forces in 
the microdevice. It this way, this will hopefully help in the culturing of CTCs which are 
important in the study of cancer stem cells and therapeutic treatments (Kaiser 2010).  
 
Figure 6.2 illustrates the enumeration of CTCs from all 10 patients. From each of the 
EDTA tubes, experimental splits of 1 ml, 2 ml and 3 ml of whole blood were set aside. It 






























Processed Blood Volume (ml)
Figure 6.2 Isolated CTCs from different volumes of blood from the each of the 10 specimens 
to investigate the linearity of the capture. A linear curve fit was performed on each sample 
with an intercept at 0. 
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was observed that a range between 0 and 53 CTCs per ml of blood was obtained for this 
study. The results of each trial were curve fitted using a straight line that passed through 
the origin to determine the linearity of the data. Theoretically, the values should follow a 
linear relationship as it is assumed that CTCs are distributed homogeneously throughout 
the blood specimen and thus it will not matter how much blood is being processed. We 
derived the goodness of fit with a linear model for each of the patient sample and listed 
them in table 6.1. For 7 out of 10 cases, it was noted that a R
2
 value of 0.9 or greater were 
attained that indicated a clear linear correlation.  
 
To further examine the discrepancies associated with certain patient samples, we divided 
the 10 samples into 2 groups based on the average quantity of CTCs detected in each of 
the samples as denoted in table 6.1. It was observed that for samples having a good linear 
relationship, it was achieved when the concentration of CTCs were larger than 5 CTCs 
per ml of blood. The R
2
 values in this group cover over than range of 0.92 to 1.00. As the 
concentration of CTCs in blood increases, the linear correlation is better defined. This 
 
Table 6.1 Linear correlation coefficient, R
2




1 2 3 4 5 6 7 8 9 10 
R
2
 0.94 0.92 0.99 0.80 0.00 0.97 0.99 1.00 0.79 0.91 
CTCs/ml 
 >5* 
Yes Yes Yes No No Yes Yes Yes No No 
* The value is calculated based on an average CTCs count of all the samples tested ie. For Patient 1 who had 7, 16 
and 30 CTCs detected in 1ml, 2ml and 3ml of blood specimens respectively had an average of (7+16+30)/(1+2+3) 
= 9 CTCs/ml (rounded up) 
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could be clearly seen with specimens taken from patients 3 and 8 (figure 6.2) where the 
correlation coefficients were 0.99 and 1.00 respectively.  
 
Henceforth, it can be inferred that with a CTC concentration of larger than 5 in the 
sample, sampling volume of 1 ml is sufficient. As an added safety factor, we proposed to 
increase the sampling volume to 2 ml instead to boost the CTC count so that the results 
were more sensitive, given a larger quantity of isolated cells. This investigation also 
demonstrated the suitability of the technique on clinical blood samples. 
 
 
6.1.3 Technical Stability for Blood Processing in the Microfluidic Device 
 
We investigated the effects of blood storage time prior to sample processing and defined 
that as the stability of the system. Although blood specimens are kept in EDTA tubes 
before being processed in the microdevice, the deterioration of the sample is inevitable 
due to the environment we reside in. As the quality of the sample worsens, it can be 
expected that there will be more coagulated clumps of blood cells present in the samples. 
For instance, repeated freeze thaw cycles can result in the formation of large precipitates 
(Cheng, Hochlowski et al. 2003). Such situations commonly arise during the 
transportation route, in between blood extraction and the delivery of the specimens from 
the hospital to the laboratory, where the blood processing is performed. This is 
detrimental to the processing of the specimen in minuscule platforms (Pan 2004) as these 




The stability of the microdevice to process blood samples is important as it determines 
the overall effectiveness of the system. This prevents wastage of valuable samples and 
allows for the logistic planning of blood extraction to maximize output. Figure 6.3 
illustrates the overview of the interior of the microdevice after the processing of blood. 
The isolated cells underwent a secondary detection procedure using immunofluorescence 
to further confirm their status and to allow a comparable platform with other techniques. 
Figure 6.3 CTCs detection from the peripheral blood of cancer patients. (a) Overview of one 
compartment in the microdevice. The red squares highlights the confirmed CTCs isolated 
from blood specimens and the circle encompasses the WBCs. Scale bar represents 50 µm (b) 
Real time visualization of the blood processing process. Scale bar represents 20 µm (c) Same 
view of the isolated cell after a washing cycle which removes blood residues. Scale bar 









Figure 6.3a depicts the overview of a compartment of isolation traps in the microdevice 
after the staining process which clearly distinguishes apart the CTCs from residual 
hematopoietic cells that remains in the system. Figure 6.3b and 6.3c show the 
intermediary steps during the blood processing and washing cycle that removes blood 
residual off the microdevice. The isolated cells can then proceed further for 
immunofluorescence detection for CTCs. A clear imagery of isolated cells was seen in 
real time during blood processing as whole blood passes through the microdevice. Being 
optical transparent and compatible with existing microscopes, the microfluidic device and 
the setup permitted visualization during the process, allowing corrections to the system if 
errors or clumps enter the platform. In addition, cells that are of larger dimensions and 
higher stiffness will be actively impeded and can be observed instantaneously.  
 
A total of 119 blood specimens from both healthy volunteers and RCC patients are 
analyzed and summarized in table 6.2. We extracted 20 control samples from 10 healthy 
volunteers and 99 specimens from 32 renal cancer patients. Hence, an average of 2 
samples was taken from each healthy volunteer and 3 from each cancer patient. Samples 
are categorized by the duration of storage before blood processing and gauged by the 
microdevice’s ability to successfully analyze these samples. As noted earlier, the quality 
of the samples are of paramount importance to the successful blood processing. For 
healthy volunteers, blood processing through the microdevice either before or after 24 hrs 
possed no significant problems. However, for RCC patients, the stability of the system 
was 85.5% for samples that were being processed within 24 hrs after blood extraction. A 
significant decline was also seen with older samples that were kept for more than 24 hrs 
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as shown in table 6.2. The discrepancies are attributed to the fast deterioration of clinical 
samples where large clumps start to form over time in the stationary EDTA tubes. These 
are likely incurred during the idle and transportation times. As the microdevice operates 
within a small enclosed volume, such coagulated materials are detrimental to the blood 
processing and likely to obstruct the microfluidic device.  
 
It is thus recommended that the storage to processing time be kept within 24 hrs after 
blood extraction. Furthermore, to prevent the formation of precipitates in the specimen, it 
is proposed to keep specimens cool and under a slight agitation using a slow rocking 
mechanism on a shaker until blood processing is available.  
 
 
6.1.4 Sensitivity for CTCs Detection using Physical Separation 
 
The detection of CTCs in RCC is attractive as it is reported that the dissemination of 
tumor cells into the circulation is an early event (Blumke, Bilkenroth et al. 2005). Studies 
Table 6.2 Stability of the microfluidic device on the detection of circulating tumor cells in 
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have also shown that CTCs are present in RCC patients with different tumor grades 
(McKiernan, Buttyan et al. 1999), indicating a high probability of detecting these 
circulating cells. There are reported significant prognostic values of CTCs enumeration 
for RCC patients (Buchner, Riesenberg et al. 2006; Bluemke, Bilkenroth et al. 2009) and 
current methods focuses on immunomagnetic separation to enrich CTCs (Bilkenroth, 
Taubert et al. 2001; Allard, Matera et al. 2004). The sensitivities of such systems can be 
affected by the selection of antibodies during enrichment, as specific renal tumor markers 
are lacking (Loberg, Fridman et al. 2004). Physical methods are attractive as it does not 
rely upon specific biomarkers on the tumor cells and are efficient in cell separation 
(Pamme 2007). The lung, being a prominent site for secondary tumor formation (Assouad, 
Petkova et al. 2007) is an excellent in vivo example to illustrate that size based arrest of 
tumor cells are possible. As shown in various reports, the lung has been effective at 
arresting CTCs by impeding them in small capillaries and exerting lethal mechanical 
trauma to these cells, which contributes to the inefficiency of the metastatic process 
(Weiss and Dimitrov 1986).  
 
Analogous to the principle of CTCs trapping in the lungs, the microdevice provides an 
efficient enrichment process using the physical differences of CTCs to blood constituents. 
By controlling the flow conditions inside the microdevice, the highly deformable 
erythrocytes (Shelby, White et al. 2003) and leukocytes (Yap and Kamm 2005) are 
removed as these cells traverse through without much difficulty, and arresting CTCs 
which are generally larger and less deformable. Figure 6.3a shows the successful 
isolation of cells with positive responses for pan-cytokeratin and DAPI. A summary of 
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the results are presented in figure 6.4 and table 6.3. A total of 73 blood samples from 
renal cancer patients which have been successfully processed by the system are tested 
using immunofluorescence staining for pan-Cytokeratin, CD45 and DAPI. A positive 
count of CTC is determined to be pan-Cytokeratin positive, CD45 negative and DAPI 
positive. A close up view of isolated CTCs and WBCs are illustrated in figure 6.5. The 
secondary anti-bodies which are tagged to the fluorophores determine the colour of the 
stains and can be interchange based on the complementary pair on the primary anti-body. 
The selection of anti-bodies using this technique is thus versatile and can be tailored to 





























Circulating Tumor Cell Counts in Peripheral Blood
 
 





n=0 n=0 n=0 n=0 
n=11 
n=35 
Figure 6.4 Isolated CTC count in renal cancer patients blood in comparison with healthy 
volunteers. The variable n denotes the number of specimens within the range. 
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Alexafluor 568 showing a red fluorescence and can be readily changed with other 
secondary antibodies to display CTCs in other colours. CTCs are detected in 70 out of 73 
samples, achieving a 95.9% detection rate in RCC patients.  
 
This is a significant increase in sensitivity comparing with previous studies (Allendorf, 
Ippagunta et al. 2004) and is likely a result of the direct processing of whole blood and 
Table 6.3 Summary of CTCs enumeration with metastatic renal cell carcinoma patients 
showing the sensitivity and purity of the system  
 
Sample Size Mean ± SD 
Positive 
Rate 




20 0 0% NA 




Figure 6.5 General view of the microdevice showing isolated CTCs (pan-cytokeratin positive, 
CD45 negative, DAPI positive) and a hematopoietic cell (pan-cytokeratin negative, CD45 
positive, DAPI positive). 
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the redundancy of a selection antibody used in immunomagnetic separation. By 
processing whole blood directly, it minimizes any potential loss from any intermediary 
preparation steps and the isolation methodology retains every cell that are physically 
different. For the samples tested, an average count of 27 CTCs was detected in the 
peripheral blood from all patient samples. Furthermore, the spread of the data comparing 
across different specimens was contrasting which can be useful to better differentiate and 
gauge the severity of the disease. Previous studies by Allard et al. (Allard, Matera et al. 
2004) presented a 25% detection rate using CellSearch’s affinity based separation and 
having positive samples with 2 cells or less with renal cancer patients. Such detection 
numbers are likely to pose issues in the linearity of the results as mentioned in section 
6.1.2 which may be erroneous when used to determine the average concentration of 
CTCs in peripheral blood. Using the same data range, it was observed that there was a 
better spread of samples in each of the data bins as illustrated in figure 6.4. However, it 
was noted that the nature of the samples and patients conditions presented were different 
in both cases which could be the reason for the dissimilarities as well. This also made a 
direct comparison difficult.  
 
For the capture purity in the microdevice, the average rate was approximately 71.5% and 
a 95% confidence interval of 64.9% to 78.1%. The large spread of purity values was 
likely a direct consequence of the different conditions of blood being processed. It was 
observed that the quality of samples was an important parameter in obtaining good 
capture purity. Samples that were significantly deteriorated tend to have more WBCs 
trapped after blood processing. 
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Nonetheless, achieving a 95.9% positive detection rate from a random selection of renal 
cancer patients proved the technology promising in the detection of CTCs. We had also 
achieved a significant sensitivity for the investigated set of blood specimens using the 
microdevice with an average detection rate of 27 tumor cells. The platform will provide a 
sensitive and accurate measure of the quantity of CTCs in peripheral blood for various 
clinical applications. For control experiments, there were no positive responses from 




6.1.5 Heterogeneous Behaviour in RCC CTCs 
 
The molecular characteristics are different for various cancer types and thus it is expected 
that such variations manifest in the circulating cells as well. Comparing against cancer of 
different origins, it is reported that these distinct divergent features are important to 
achieve a good understanding of the disease and for prognostic purposes (Riethdorf, 
Wikman et al. 2008; Steen, Nemunaitis et al. 2008). Within circulating cells of the same 
type, such disparities are also present. Sieuwerts et al. (Sieuwerts, Kraan et al. 2009) 
observed that for breast cancer cell lines, a diverse expression pattern of EpCAM existed 
which may limit its usefulness in it use for cell separation as potential cancer cells with 
low EpCAM levels are not detected.  Hautkappe et al. (Hautkappe, Lu et al. 2000) also 
reported the detection of specific mutations in the von Hindel-Lindau tumor-suppressor 
gene in CTCs of renal cancer patients, showing diversities in cancer cell populations. 
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These studies demonstrated that the pursuit to decipher the differences that existed in 
CTCs will be clinical beneficial.  
 
We had also observed various heterogeneous behaviours in the isolated CTCs from renal 
cancer patients in the microdevice. A clear distinction was in the pan-cytokeratin 
expression levels detected across different blood specimens, which was used to confirm 
the presence of CTCs. Within isolated cells in the sample blood sample, the expression 
patterns were also varied and could be clearly observed under the microscope. Figure 6.6 
Isolated cells with 
varying degree of CK 
expression level 
Figure 6.6 Isolated cells from peripheral blood of patients. Identification using pan-cytokeratin 




depicts a fluorescent image of isolated cells from a patient’s peripheral blood which 
clearly demonstrated CTC variants having different pan-cytokeratin expression levels. 
Most of the isolated CTCs tend to show weak pan-cytokeratin staining while small 
proportions display distinct expression levels. These results are in coherence with 
previous studies conducted by Blumke et al (Blumke, Bilkenroth et al. 2005), having 
shown using immunocytochemistry that cytokeratin expression levels in RCC CTCs 
differs. The observation is intriguing and likely to suggest the presence of diverse 
populations of cells within the same cancer type in our specimens.  
 
In addition, another interesting result from our tests shows a diverse variation in cell sizes 
of CTCs. The different dimensions of cells were rather uniformly distributed for all the 
CTCs isolated from the 73 blood samples. The difference between the smallest and 
largest cell was however rather distinct with isolated CTCs as small as 8 µm to cells as 
large as 30 µm which were pan-cytokeratin positive, CD45 negative and DAPI positive.   
Figure 6.7 is a clear illustration of the differences, with the isolated cells in the traps and 
showing positive responses fluorescently for CTC markers. The voluminous ratios of the 
cell nucleus to its cytoplasm were large which typically are characteristics observed in 
cancer cells. These are features that can be observed in figures 6.6 and 6.7 and also in all 
other isolated cells from the tests. 
 
The design of the microdevice initially targeted to hold cells in the size range of 15 µm to 
25 µm, and the presence of smaller cells resulted in traps holding more than 1 cell at 
times. The ability to hold CTCs below the desired range indicated that the stiffness of the 
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cells is significantly dissimilar enough to be impeded by the isolation structures. An 
example of trapping a small CTC is visibly demonstrated in figure 6.7. The results are 
also likely to indicate the diverse and complex nature of CTCs in haematogenous 
metastasis. It concurs with various hypotheses from numerous studies that a diverse 
group of circulating cells are present in peripheral blood (Racila, Euhus et al. 1998; 
Sledge 2006; Pantel and Alix-Panabieres 2007; Pantel, Brakenhoff et al. 2008; Sastre, 
Maestro et al. 2008; Sergeant, Penninckx et al. 2008). The capability to isolate the 
different subtypes of CTCs is useful for further characterizations which might be valuable 




DAPI CD45 panCK Merged 
Figure 6.7 Isolated cells from peripheral blood of RCC patients and immunofluorescence 
staining in situ on chip. (b) Isolated CTCs of various sizes showing pan-cytokeratin positive, 
CD45 negative and DAPI positive. Scale bar represents 5 µm. 
127 
 
6.1.6 CD44 Staining of CTCs in RCC patients  
 
The system is shown to be suitable to handle the challenges involved in the finding of 
CTCs, with a high detection rate in the peripheral blood of cancer patients. Heterogeneity 
of the circulating cells are also important study parameters and physical techniques for 
enrichment and detection of CTCs will further the endeavour. By using cell and 
deformability of cells for tumor cell isolation, it relies solely upon the differences in 
biorheological properties and will retain all cells that are significantly different than 
blood constituents. This is in contrast to the use of biomarkers for CTCs enrichment 
which select a specific cell population as the markers are not entirely universal. Thus, the 
outcomes of using physical separation are likely to encompass a more diverse and 
unbiased range.  
 
From the trials, 94.5% of the 73 blood samples presented additional mono-nucleated cells 
that were negative for both pan-cytokeratin and the hematopoietic marker (CD45). 
Though they were negative for standard CTCs selection markers, their physical 
characteristics such as the voluminous ratio of their nucleus to cytoplasmic content were 
large which was suggestive that they might be cancer cells. Furthermore their lack of 
positive response to hematopoietic markers indicated that these cells were not of blood 
origin. Blumke et al (Bluemke, Bilkenroth et al. 2009) also reported the presence of 
cytokeratin negative large cells in RCC patients using a CD45 depletion technique that 
removes leukocytes in an enriched sample after density gradient centrifugation, which 
showed that there were probably significant numbers of cancer cell subpopulations in 
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peripheral blood. It should be noted that these samples used in our tests were derived 
from patients with metastatic renal cell carcinoma, and may not represent the entire 
spectrum of patients with RCC.  
 
CD44 that belongs to a family of transmembrane glycoprotein is shown to be associated 
with p53 expression (Zolota, Tsamandas et al. 2002) and has prognostic potential in RCC 
(Paradis, Ferlicot et al. 1999). Studies have also revealed strong correlations of CD44 
expressions to tumor differentiation and cancer progression (Heider, Ratschek et al. 1996; 
Terpe, Storkel et al. 1996; Masuda, Takano et al. 1999). We investigated the expression 
patterns of CD44 standard form in CTCs by direct immunofluorescence techniques and 
staining the isolated cells in situ. 10 samples were randomly selected from the entire tests 



























and repeated for the detection of pan-cytokeratin, CD44 and DAPI. We allowed the 
samples to be processed in parallel with two different microdevices at the same time, 
using blood samples from the same EDTA tubes. Different sets of primary antibodies are 
then added during the immunofluorescence staining process. The results are summarized 
in figure 6.8 with all the samples having a proportion of isolated cells positive for the 
standard CTC markers (pan-cytokeratin positive, CD45 negative and DAPI positive). In 
the parallel setup, 3 subtypes could be seen, namely isolated cells that were pan-
cytokeratin positive/CD44 negative; both positives and pan-Cytokeratin negative/CD44 
positive. A proportion of the isolated cells from all 10 samples were pan-Cytokeratin 
positive/CD44 negative. 5 out of 10 samples had isolated cells that were positive for both 
and 7 out of 10 had isolated cells only for CD44. Figure 6.9 shows a typical analysis from 
the samples illustrating the distinct expression patterns that are present. The results are 
indicative of the occurrence of CTC subtypes and the complex nature of tumor cells 
(a) 
(b) 
panCK CD44 DAPI Merged 
Figure 6.9 Immunofluorescence staining of pan-Cytokeratin and CD44 in RCC CTCs which 
show a heterogeneous cell population in the isolated cells by the microdevice. (a) Isolated cell 
with CD44 positive, pan-cytokeratin negative and DAPI positive. (b) Isolated cell with CD44 




dissemination into the blood circulation. The lack of CD44 in normal renal cells (Paradis, 
Ferlicot et al. 1999) suggest that CD44 can be a strong prognostic factor to detect CTCs 
in peripheral blood. 
 
 
6.2 Non Small Cell Lung Cancer (NSCLC) and Nasopharyngeal Cancer (NPC) 
 
Having optimized the system with controlled parameters described in chapter 5, the 
microdevice was tested initially on blood specimens from renal cancer patients. The 
benefits of CTC enumeration are being less invasive than surgical biopsies and can 
potentially be more responsive to the state of health of cancer patients (Mocellin, Hoon et 
al. 2006; Riethdorf, Wikman et al. 2008). In addition, it can provide an alternative source 
of tumor tissue for the detection, characterisation and monitoring of non-blood-related 
cancers (Maheswaran, Sequist et al. 2008; Panteleakou, Lembessis et al. 2009). The 
technique proposed in this report uses a microfluidic device which isolates CTCs directly 
from whole blood using purely rheological differences. Tumor cells which lack certain 
blood characteristics made them physically distinct from blood cells. This feature is 
probably not restricted to renal cancer alone and has been clearly demonstrated with a 
diverse range of cancer cell lines tested. The technique is potentially universal to handle 
most cancer types of non hematologic origin.  
 
In a subsequent study, the platform was tested on clinical blood specimens from patients 
suffering from lung and nasopharyngeal cancer. Blood extraction followed protocols set 
out in sections 3.4 and 3.9 after obtaining consent from patients for the tests, as stipulated 
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by the Institutional Review Board. The study is currently ongoing in parallel with other 
trials. For the tests on NSCLC and NPC, a total of 7 patients are currently involved in the 
trials. Figure 6.10 shows some of the isolated cells from the blood specimens. The 
isolated cells underwent an immunofluorescent labeling for cytokeratin, CD45 and DAPI 
which was similar to the procedures performed on RCC samples. Figure 6.10a shows the 
positively identified tumor cells from lung cancer patients. The isolated cells also showed 
typical large cell nucleuses which are clearly visible in figure 6.10b. Other physical 
Figure 6.10 CTC isolation from clinical blood samples of metastatic lung cancer patients. 
(a) Immunofluorescence staining of isolated cells to identify cancer and hematopoietic 
cells. Scale bar represents 20 µm. (b) Phase contrast images of isolated CTCs after blood 




CD45 panCK DAPI Merged 
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characteristics concur with earlier deductions such as isolated cells display a wide range 
of sizes and were heterogeneous in behavior.  
 
Table 6.4 summarizes the CTCs isolation and detection of NSCLC and NPC specimens. 
A 100% detection rate was achieved for both cancer types. This was indicative of the 
suitability of the technique and the microdevice to perform the tasks. Comparing with 
leading technologies on CTC enumeration for lung cancer (Allard, Matera et al. 2004; 
Maheswaran, Sequist et al. 2008), the sensitivity of the system showed comparable 
isolation efficiencies to work on patients’ blood samples. An average cell count of 63 
cells was obtained with specimens from lung cancer patients and a positive count of 70 
cells for the NPC specimen. An average capture purity of 85.5% was achieved for lung 
cancer samples and a 95% confidence interval gave the range from 78.6% to 92.3%.  
 
Table 6.4 CTCs isolation and detection from peripheral blood of metastatic lung cancer 












1 NSCLC 2 ml 30 4 88.2 
2 NSCLC 2 ml 84 10 89.4 
3 NSCLC 2 ml 82 10 89.1 
4 NSCLC 2 ml 20 8 71.4 
5 NSCLC 2 ml 36 11 76.6 
6 NSCLC 2 ml 166 4 97.6 
7 NSCLC 2 ml 79 3 96.3 
8 NSCLC 2 ml 3 1 75.0 




The results from the tests showed a high signal to noise ratio that is beneficial for 
downstream processing, especially for the molecular detection methods to avoid false 
positives. It is also evident that physical dissimilarities between CTCs and blood 
constituents are significant in peripheral blood of cancer patients for an efficient tumor 
cell enrichment and separation. The methodology for the separation and isolation of 
CTCs from blood offers a new perspective to current performed techniques and will aid 
clinical applications to target the disease.  
 
A sum up of all the results from clinical samples is shown in table 6.5. With clinical 
blood specimens from cancer patients, it is demonstrated that the system is sensitive to 
rare CTCs from various cancer types. This is potentially useful to gauge the disease 
severity, drug monitoring and prognostic purposes in clinical practices, which will 
hopefully aid and raise the patients’ quality of life. The microdevice is specific in its 
blood processing which showed negative responses from all 10 healthy volunteers who 
participated in the study. The CTCs yield from the isolation process was large and 








Mean n = 0 n ≤ 5 ≤ 10 ≤ 50 > 50 
Healthy 
Volunteers 
10 20 0 20 0 0 0 0 
RCC 32 73 27 3 17 7 35 11 
NSCLC 6 8 63 0 1 0 3 4 





covered a wide range as shown in table 6.5. This is valuable to the further analyses of 
CTCs in cancer patients to better understand the disease.   
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Cancer metastasis is the key attribute to cancer-related deaths and much remains to be 
explored about this phenomena. Evolving techniques for isolating CTCs represents an 
unprecedented opportunity for clinical and biological insight into the nature of metastasis 
and cancer. In the present study, it is demonstrated that a microfluidic setup can yield an 
accurate and sensitive measure of CTCs in peripheral blood. CTCs which represent tumor 
cells in the blood circulation of cancer patients are likely to be useful and associated to 
the disease. The basis for an effective isolation of CTCs is to utilize their inherent 
physical differences of size and deformability from blood cells in a microfluidic system. 
With the platform, the objectives are to study these cells in circulation, with hopes to 
understand their characteristics in relation to the metastatic process. 
 
Using computational analysis, various design layouts were put forward and tested in a 
systematic and controlled manner to show that the proposed system was plausible to 
handle the tasks. The proposed system was then tested with spiked samples using 
numerous cancer cell lines. Results from the tests showed that the microfluidic platform 
is successful in the isolation of various cancer cell types. The microdevice also achieved 
significant cancer cell isolation purity while preserving the integrity and state of these 
cells. Furthermore, the microfluidic platform is versatile, being capable of handling 
diverse cancer cell lines with minimal noise and yet maintaining cell viability and 
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phenotype through a gentle and straightforward processing. More importantly, the system 
is label-free, isolating cells in an unbiased fashion, and sensitive to detect small cancer 
cell count in the specimens. Through the use of distinctive biomechanical characteristics 
of the cells, neither functional modification nor complex enrichment procedures were 
required. Being label free also helped to address numerous concerns linked to affinity 
based isolation methods. Operational procedures were straightforward as minimal 
preparations were needed for the microdevice and samples. Cancer cells were captured in 
a single processing step thereby minimizing potential cell losses during intermediary 
procedures. Furthermore, immunofluorescence staining could be done in situ inside the 
microdevice as the system is optical transparent and designed to be integrated onto 
existing microscopes. Given the simplicity of the processing procedures, multiplexing of 
the system to concurrently run numerous samples is straightforward, which allowed 
processing and testing more parameters at the same time.   
 
With clinical blood specimens from patients suffering from various cancer types, there 
was positive CTC detection in the preliminary studies, which was also promising for the 
isolation of viable cells. The microdevice which separates CTCs in a single step, without 
requiring biochemical modifications is attractive to maximize the yield for downstream 
analyses to enhance the understanding of the disease, and complement current cancer 
detection and prognosis techniques. Results obtained from RCC peripheral blood samples 
highlighted the heterogeneous nature of CTCs in haematogenous metastasis which 
presented variations in cell dimensions and pan-cytokeratin expression levels. The 
isolated cells also revealed the presence of CD44 in CTCs arising from the peripheral 
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blood of RCC patients which had shown in previous immunohistochemistry studies to 
have strong correlations to tumor progression. The microfluidic platform was capable of 
isolating the different subtypes of CTCs which is useful for further characterizations. The 
microsystem also allowed for real time visualization of the isolation process. With blood 
specimens from lung and nasopharyngeal cancer, the investigation presented a strong 
affinity to enrich and isolate these cells. The microdevice which separates CTCs in a 
single step without requiring biochemical modifications, is attractive for applications in 





Moving forward, the system is currently in the process of testing various clinical 
specimens from cancer patients to determine the disease correlation, as well as to engage 
in the study of the epigenetics of the disease. Most clinical trials are currently still in 
progress and as the tests are done single blinded, such data are not available at this time. 
These trials are likely to continue over an extended period to track the progress of the 
patients. The work is also expected to expand into the molecular aspects of the problem 
which will help to identify genes and proteins that are involved in the disease. The 
current system can be optimized to fulfill the objectives by providing access to the 
recovered cells for DNA extraction and fluorescence in situ hybridization (FISH) 
analyses. With multiplexing of the setup to be straightforward as demonstrated, these 




Furthermore, there are interests in the culture of CTCs in vitro and the system might be 
well poised to address these issues. Current limitations in this aspect of the study is in 
getting enough living cells for culture and may be addressed with larger volumes of 
extracted blood from the patients. The system will then have to be scaled up to meet the 
volume requirements. In addition, to improve upon current work, the designs of the 
isolation traps can be modified. For instance, a diverse range of cell diameters were 
observed in isolated CTCs which led to multiple cells within each isolation trap in some 
instances. A slight modification of design to have different sizes of traps in the same 
microdevice will address the discrepancies.  
 
Minor improvements to the blood processing procedure may be implemented in the 
future such as the incorporation of an automated CTC counter from the isolation traps. 
This is crucial with the scaled up system meant for processing larger blood volumes, as it 
will likely incur a higher probability of human error during cell enumeration. Automated 
CTC counting will also ensure consistencies in the tests. Further efforts to improve upon 
the design of the microchip to allow greater flexibility in processing blood samples are 
also currently being pursued. Finally, it is of interest to explore other microdevice designs 
in the future work that utilizes similar separation mechanisms of CTCs from whole blood 
with the objectives of achieving better isolation efficiencies and shorter blood processing 




In summary, our platform provides a unique opportunity to study the systemic circulation 
and activity of cancer in a simple, accessible and unbiased fashion over time. We 
anticipate its use in disease prognosis and therapeutic monitoring, thereby permitting 
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